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INTRODUCTION 
DRUG DISCOVERY [1-3,8] 
Drug discovery and development is a research process that identifies a new 
chemical entity and brings out its capabilities by designing and screening proper 
biochemical targets. It is an innovative science in which both knowledge and 
technologies are incorporated to convert a chemical moiety into useful therapeutic 
drugs. 
The discovery and development process of novel drugs generally takes a 
long time and it is recognized to be, risky and costly. It takes approximately  
14 years to fulfil the typical drug discovery process and development cycle from 
concept to market and the cost ranges from 0.8 to 1.0 billion USD. Rapid 
developments in combinatorial chemistry and high-throughput screening 
technologies have provided an environment to expedite the drug discovery process 
by enabling huge libraries of compounds to be screened and synthesized in short 
time. Although the investment in new drug development has grown significantly in 
the past decades, the output is not directly proportional to the investment because 
of the low efficacy and high failure rate in drug discovery. Consequently, various 
approaches have been developed to shorten the research cycle and reduce the 
expense and risk of failure for drug discovery. Computer-aided drug design 
(CADD) is one of the most effective methods for reaching these goals. 
CADD is a widely used term that represents computational tools and sources 
for the storage, management, analysis and modelling of compounds. It covers many 
aspects of drug discovery, including computer programs for designing compounds, 
tools for systematically assessing potential lead candidates and the development of 
digital repositories for studying chemical interactions. In the post genomic era, 
benefiting from the dramatic increase in bio-macromolecule and small molecule 
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information, computational tools can be applied to most aspects of drug discovery 
and development process, from target identification and validation to lead discovery 
and optimization; the tools can even be applied to preclinical trials, which greatly 
alters the pipeline for drug discovery and development. The use of computational 
tools could reduce the cost of drug development by 50%. 
The efficiency, accuracy and speed of the computational methods largely 
depend on several technical aspects, including conformation generation and 
sampling, scoring functions, optimization algorithms, and molecular similarity 
calculations. 
RATIONAL DRUG DESIGN [4,5] 
The need for on-going development of new drug needs to emphasise in light 
of the current global situation of health and disease. Traditionally, the process of 
drug development has revolved around a screening approach, as nobody knows 
which compound or approach could serve as a drug or therapy. The short coming 
of traditional drug discovery; as well as the allure of a more deterministic approach 
to combating disease has led to the concept of “Rational Drug Design”.  
One cannot design a drug without knowing more about the disease or 
infectious process than the past. The first necessary step for “rational” design is the 
identification of a molecular target critical to a disease process or an infectious 
pathogen. Then the important prerequisite of “drug design” is the determination of 
the molecular structure of target, which makes sense of the word “rational”. In fact 
the validity of “rational” or “structure based” drug discovery rests largely on a high 
resolution target structure of sufficient molecule detail to allow selectivity in the 
screening of compounds. 
The concept of rational drug design simply lies in logical reasoning before 
designing any therapeutic agents. For example, to prepare any competitive inhibitor 
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of a particular target, the logic of predicting the structure is to simply design a 
molecule with similar structural features exhibited by the endogenous agents or by 
closely examining the active binding site. Close examination of the active sites 
gives many hints about the interacting amino acid residues, So it becomes simple 
to predict the nature and type of substituent and the favourable position in the 
molecule, which will favour better binding. 
Aims of drug design 
 To improve potency 
 To modify specificity of action 
 To improve duration of action 
 To reduce toxicity 
 To effect ease of application or administration or handling 
 To improve stability 
 To reduce cost of production 
TYPES OF DRUG DESIGN [6-8] 
 Ligand based drug design 
 Structure based drug design 
Ligand Based Drug Design (LBDD)  
LBBD is also known as indirect drug design this method is used in the 
absence of the structural information of the target to know about inhibitors for the 
target receptor. Biologically active lead molecule is detected by using structural or 
topological similarity or pharmacophoric similarity properties. Several criteria are 
used for similarity comparisons such as structure as well as shape of individual 
fragment or electrostatic properties of the molecule. The generated lead molecules 
are ranked based on their similarity score or obtained by using different methods or 
algorithms.  
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Structure Based Drug Design (SBDD)  
SBDD is also known as direct drug design. It depends on the knowledge of 
3D structure of the biological target that is obtained via methods such as X-ray 
crystallography, NMR spectroscopy or homology modelling. When the 
experimental structure is unavailable this method is used to create a homology 
model of the target. With the three dimensional structure of the target obtained from 
X-ray crystallography or NMR spectroscopy, one can begin the search for a ligand 
whose orientation and conformation is complimentary to the receptor structure. 
This type of drug design requires the receptor’s complete structural knowledge and 
the tools to design extremely specific molecule that interact with the receptor. 
Therefore, structures of the target molecules have to be decided and the exact ligand 
molecule need to be designed. Hence, any one of the following parameter should 
be available to start a structural based drug design:  
 3 dimensional structure of the target macromolecule  
 3 dimensional structure of a closely related analogue  
DRUG DISCOVERY METHODS [9,10] 
1.  Real screening  
2.  Virtual screening  
Real Screening  
Real screenings include methods like high-throughput screening (HTS) 
which can experimentally check the activity of hundreds or thousands of 
compounds against the particular target limited time. Although highly expensive, it 
provides real results which can be used for drug discovery.  
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Virtual Screening 
The application of computers and computational methods to select or 
prioritize molecules for experimental screening is known as virtual screening. Thus 
a large percentage of the proposed analogue can be eliminated, and those molecules 
with the highest probability to show biological activity can be selected. The time 
and cost associated with the production of libraries for screening can be 
considerably reduced by adopting this methodology. 
STEPS INVOLVED IN DRUG DESIGN[7] 
The drug design process may be categorized into the following four distinct 
stages:  
1.  Selection and identification of the target.  
2.  Search for lead or lead identification.  
3.  Lead optimization.  
4.  Synthesis of new molecules.  
1.  Selection and identification of the target 
The process of drug discovery begins with the identification of a possible 
therapeutic target. The selected drug target must be a key molecule involved in a 
specific metabolic or cell signalling pathway that is known or believed to be related 
to a particular disease state.  
Important drug targets include:  
 Enzymes (inhibitor- reversible or irreversible)  
 Receptors (agonist or antagonist)  
 Nucleic acid intercalators or modifiers  
 Ion channels (blockers or openers)  
 Transporters (uptake inhibitors)  
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The 3D structure of the protein target is usually obtained by X-ray 
crystallography [crystal structures of different macromolecules can be obtained 
from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Database], Nuclear Magnetic Resonance (NMR) or homology modeling from a 
previously determined structure.  
2.  Search for lead (lead identification)  
Lead structures are ligands which are selected from a series of related 
compounds that exhibit suboptimal target binding affinity. After lead selection, they 
are tested for their activity towards a desired drug target.  
i) De novo molecular design  
This approach is used to design new structures by sequentially adding 
molecular fragments to a growing structure or by adding functionality to an 
appropriately sized molecular scaffold.  
ii) Database search methods  
The lead molecules can be selected by screening structures found in various 
chemical databases which contain an ocean of scaffolds.  
iii)  Combinatorial methods  
With the help of combinatorial chemistry we can create a large library of 
varied molecular structures by using a single scaffold and diverse array of reactants.  
3.  Lead optimization  
Lead optimization is a process in which lead compounds are altered to make 
them more effective and safer i.e., to achieve maximum affinity to the target with 
improved bioavailability and low toxicity. The properties of the lead compound can 
be modified by effective combination of two or more active moieties or by 
elimination or substitution of various groups.  
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ADMET Studies[11] 
Nowadays, testing of drug metabolism, pharmacokinetics and toxicity are 
done before evaluating a compound in the clinic. The rate at which the biological 
screening data obtained has significantly increased and high-throughput screening 
(HTS) facilities are now widespread at large pharmaceutical companies. 
Combinatorial chemistry makes larger sequence of closely related libraries of 
chemicals using the same chemical reaction and appropriate reagents. Such libraries 
are run through the HTS to make hits and which further, more focussed, and then 
their series are designed in the next round. 
             As the capability for biological screening and chemical synthesis have 
dramatically increased, the demands for large quantities of early information on 
absorption, distribution, metabolism, excretion, toxicity (ADMET) (together called 
ADMET data) also have increased simultaneously. Various medium and high 
throughput in vitro ADMET screens are therefore now in use. Before the 
pharmaceutical development of molecules for the treatment of disease it is 
recommended that the pharmacokinetic properties of each compound should be 
considered prior to its selection as drug candidate. 
            Again, there is an increasing need for good tools for predicting these 
properties. Various software and servers such as Accerlys accord for excel are 
available for this purpose. 
ADMET data to be predicted 
            A deeper understanding of the relationships between important ADMET 
parameters and molecular structures and properties has been used to develop  
in silico models that allow the early estimation of several ADMET properties. 
Among other important issues, we want to predict properties that provide 
information about dose size and dose frequency such as oral absorption, 
bioavailability, brain penetration, clearance and volume of distribution. 
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Need of ADMET data 
 ADME/Tox properties are important parameters for the selection of drug 
 candidates for development. 
 The need for ADMET information starts with the design of new compounds. 
 This information can influence the decision to proceed with synthesis either 
via traditional medicinal chemistry or combinatorial chemistry strategies. 
Obviously, computational approaches are the only option for getting this 
information at this stage. 
 Drug candidate selection involving both pharmacological properties and 
ADME/Tox screening should lead to an enhanced probability of clinical 
success. 
 This will inevitably save time and costs in drug discovery and development. 
ADMET properties can be influenced by various physico-chemical 
properties like 
 Molecular weight 
 Hydrogen donors 
 Hydrogen acceptors 
 Log P etc 
DRUGLIKENESS [12,13] 
Druglikeness may be defined as a complex balance of various molecular 
properties and structural features which in turn determine whether a particular 
molecule is similar to the known drugs.  
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In silico evaluation of druglikeness at an early stage involves the prediction 
of various ADMET (absorption, distribution, metabolism, excretion, toxicity) 
properties using computational approaches, i.e., it provides a preliminary prediction 
of the in vivo behaviour of a molecule. Druglikeness score towards GPCR ligands, 
ion channel modulators, kinase inhibitors, nuclear receptor ligands and protease 
inhibitors may be evaluated online by using ‘Molinspiration server. The higher the 
value of the score, the more the probability that the particular molecule will be 
active. 
LIPINSKI’S RULE OF FIVE 
Christopher A. Lipinski (1997) proposed four parameters that define the 
‘druglikeness’ of a potential drug candidate based on the observation that most 
medication drugs are relatively small and lipophilic molecules. Lipinski’s Rule of 
Five can be applied to evaluate druglikeness or determine if a chemical compound 
with a certain pharmacological or biological activity has properties that would make 
it a likely orally active drug in humans. Lipinski’s rule says that, in general, an 
orally active drug has not more than one violation of the following criteria:  
 Not more than 5 hydrogen bond donors (sum of OHs and NHs)  
 Not more than 10 hydrogen bond acceptors (sum of Ns and Os)  
 Molecular weight not greater than 500 Daltons  
 An octanol-water partition coefficient, log P, not greater than 5.  
Improvements  
To evaluate druglikeness in a better way, the rules have spawned many 
extensions by Ghoseet al. in 1999.  
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  log P : -0.4 to +5.6  
  Molecular refractivity : 40-130  
  Molecular weight : 160-500  
  Number of atoms : 20-70  
  Polar surface area must not be greater than 140 Å  
 
DOCKING[14,15] 
Docking is a method which predicts the preferred orientation of one 
molecule to a second when bound to each other to form a stable complex. Preferred 
orientation helps to predict the strength of association of or binding affinity between 
two molecules. The associations with biological molecules such as proteins, nucleic 
acids, carbohydrates and lipids play an important role in signal transduction i.e. 
agonism or antagonism. Therefore, docking is a useful tool for predicting both the 
strength and type of signal produced.  
Molecular docking may be defined as an optimization program, which 
would describe the ‘best-fit’ orientation of a ligand that binds to a particular protein 
of interest. The focus of molecular docking is to computationally stimulate the 
molecular recognition process. Molecular docking aims to achieve an optimized 
conformation for both the protein and ligand and relative orientation between 
protein and ligand such that the free energy of the overall system is minimized.  
A molecular docking calculation consists of the following steps:  
 Optimization of the ligand geometry, calculation of pH-dependent partial 
 charges and identification of rotatable bonds.  
 Calculation of electrostatic properties of the protein of interest and defining 
 the ligand –binding region.  
 Calculation of ligand-protein interaction by a scoring function that includes 
 terms and equations that describe the intermolecular energies.  
Docking produces plausible candidate structures. These candidates must be 
ranked by using scoring functions and to identify structures that are most likely to 
occur in nature.  
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Rigid-body docking and flexible docking  
If the bond angles, torsion angles and bond lengths of the components are 
not modified at any stage of complex generation, then they are known as rigid body 
docking. A rigid-body docking is sufficiently good for most docking, when 
substantial change occurs within the components at rigid-body docking. Docking 
procedures which permit flexible docking procedures or conformational change, 
must intelligently select small subset of possible conformational changes for 
consideration.  
Mechanics of docking 
To perform a docking screen, the first requirement is a structure of interested 
protein. Usually the structure has been measured using a biophysical technique such 
as X-ray crystallography or NMR spectroscopy. The protein structure and a 
database of potential ligands serve as inputs to a docking program. The success of 
a docking program is based on two components:  
 Search algorithm  
The search space includes all possible orientations and conformations of the 
protein paired with ligand. With present computing resources, it is impossible to 
exhaustively explore the search space; which involves enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations of 
ligand relative to the protein at a given level of granularity. Most docking programs 
account for a flexible ligand, and several are attempting to model a flexible protein 
receptor. Each “snapshot” of the pair is referred to as a pose. There are many 
conditions for sampling the search space. Here are some examples:  
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 Use a coarse-grained molecular dynamics simulation to propose 
energetically reasonable poses stimulation. (direct search-simplex method; 
gradient-based search-steepest descent, Fletcher-Reeves method, Newton-
Raphson method; least square methods-Marquardt method)  
 Simulated annealing (Monte Carlo search of the parameter space)  
 Use a “linear combination” multiple structures determined for the same 
protein to emulate receptor flexibility  
 Use a genetic algorithm to “evolve” new poses that are successively more 
fragment-based construction.  
 Scoring function  
The scoring function takes a pose as input, returns a number indicating the 
likelihood that the pose represents the favourable binding interaction.  
             Most scoring functions are physics based molecular mechanics force fields 
that estimate the energy of the pose; a low (negative) energy indicates a stable 
system and thus likely for a binding interaction. It is an alternative approach to 
derive a statistical potential for interactions from a large database of protein-ligand 
complexes, such as the Protein Data Bank. This evaluates the fit of the pose 
according to this inferred potential.  
There are a large number of structures from X-ray crystallography for 
complexes between proteins and high affinity ligands. It is comparatively fewer for 
low affinity ligands as the later complexes tend to be less stable and therefore more 
difficult to crystallize. Scoring function trained with this data can dock hits (ligand 
predicted to bind to the protein and actually does not, when placed together in a test 
tube).  
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Various softwares used for docking studies are:  
 AutoDock 
 Gold  
 Vega  
 Glide  
 Flexidock 
 Flex  
 Fred  
 Hint etc 
Autodock 4.2 
Autodock is a suite of automated docking tools. It is designed to predict how 
small molecules, such as substrates or drug candidates, bind to a receptor of known 
3D structure. It uses Monte Carlo method and simulated annealing in combination 
with genetic algorithm for building the possible conformations. The genetic 
algorithm is used for global optimization. Autodock works in Linux platform. 
Cygwin is used as a user friendly interface. The local search method is energy 
minimization and Amber “force field” model helps in the evaluation of binding 
positions compatible with several scoring functions based on the free energy. The 
atomic affinity grids can be visualized. This is helpful to guide organic synthetic 
chemists to design better binders. Autodock consists of two main programs:  
 AutoGrid pre-calculates the grids.  
 AutoDock perform the docking of the ligand to a set of grids describing the 
 target protein.  
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It also has got capabilities to visualize atomic affinity grids and its graphical 
user interface, thus to support the analysis of docking results. It has an advantage 
of getting free academic license, at the same time parallel computation is not 
supported. 
HYPERTENSION[16,17] 
Hypertension is one of the most common worldwide diseases affecting 
humans. Because of the associated morbidity and mortality and the cost to society 
hypertension is an important public health challenge. Over the past several decades, 
extensive research, widespread patient education, and a concerted effort on the part 
of health care professionals have led to decreased mortality and morbidity rates 
from the multiple organ damage arising from years of untreated hypertension. 
High blood pressure is the leading cause of strokes and a major risk factor 
for heart attacks, one of the most important aspects of preventive cardiology, and it 
is necessary to identify as many people who have the disease as possible and to take 
steps to lower the blood pressure before it causes damage to the blood vessels, heart, 
kidneys, eyes and other organs. It is a major health problem that challenges not only 
with health care professionals but also the pharmaceutical industries and drug 
regulatory agencies. 
Hypertension can be defined as a sustained increase in BP (140/90mm hg), 
a criteria that characterises a group of patients whose risk of hypertension related 
cardiovascular disease is high enough to merit the medical attention. Actually, the 
risk of both critical and non-critical cardiovascular disease in adult is lowest with 
systolic BP less than or equal to 120 mm hg and diastolic BP less than or equal to 
80 mm hg; these risk increase progressively with higher systolic and diastolic blood 
pressures. Acknowledgment of this continuously increases the risk that provides a 
simple definition of hypertension. 
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The risk of cardiovascular morbidity and mortality is directly correlated 
with blood pressure (BP) .Starting at a BP of 115/75 mm hg, risk of cardiovascular 
disease doubles with every 20/10 mm hg increase. Even patients with 
prehypertension have an increased risk of cardiovascular disease. Outcome trials 
have shown that antihypertensive drug therapy substantially reduces the risks of 
cardiovascular events and death. 
TYPES OF HIGH BLOOD PRESSURES[18] 
There are two main types of high blood pressure 
Essential (primary) hypertension 
 The main form of high blood pressure-accounts for around 85-95% of cases 
 Has no single identifiable cause 
 Potential causes include genetic and environmental factors  
Secondary hypertension 
 Rare form of high blood pressure. 
 Caused by another medical condition or treatment. 
 Causes include problems (renovascular hypertension), adrenal gland 
tumours, thyroid disease and narrowing of the aorta (the main artery that 
takes blood from the heart to the rest of the body). 
Other types of high blood pressure include 
 Isolated systolic hypertension- the systolic pressure (top number) is raised 
 but the diastolic pressure is normal. 
 Isolated diastolic hypertension-the diastolic pressure (bottom number) is 
 raised but the systolic pressure is normal. 
 White coat hypertension-where the blood pressure is raised due to the stress 
 of a vsit to the doctor or nurse.  
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Category of hypertension 
 
 
 
 
 
 
 
 
 
Fig 1: Category of Hypertension 
Factors that affect high blood pressure [19,20] 
There are risk factors that can contribute to developing high blood pressure. 
Some of these factors can be changed and some others cannot be changed. 
Factors that cannot be changed 
 Age 
 Race 
 Socioeconomic status 
 Family history (heredity) 
 Gender 
 Body mass  
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Factors that can be changed 
 Sodium (salt) sensitivity 
 Alcohol use 
 Birth control pills(oral contraceptive use) 
 Obesity 
 Life style and stress 
 Medication 
Anti-hypertensive therapy[21] 
The aim of therapy is straightforward: reduction of blood pressure to within 
the normal range. There are three general approaches to the treatment of 
hypertension. The first involves the use of diuretics to reduce blood volume. The 
second employs drugs that interfere with the renin-angiotensin system, and the third 
is aimed at a drug-induced reduction in peripheral vascular resistance, cardiac 
output or both. A reduction in peripheral vascular resistance can be achieved 
directly by relaxing vascular smooth muscle with drugs known as vasodilators or 
indirectly by modifying the activity of the sympathetic nervous system. 
Research in the field of hypertension has gained worldwide importance 
because of its high frequency and concomitant risks associated with cardiovascular 
diseases. It has been identified as leading risk factor for mortality and is ranked third 
as a cause of disability adjusted life-years. 
A pathophysiological view point, hypertension involves changes in at least 
one of the hemodynamic variables (cardiac output, arterial stiffness or peripheral 
resistance) that determine measurable blood pressure. Therefore each of these 
variables is a potential target for modulation. It is recognized that angiotensin 
converting enzyme (ACE) plays an important role as a regulatory sight in the renin 
angiotensin system (RAS) that control excessive activation and then hypertension. 
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RENIN ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)[21,22] 
RAAS is a powerful system, regulating fluid-electrolyte balance and 
systemic blood pressure. Renin is a proteolytic enzyme synthesized, stored and 
secreted from the juxtaglomerular apparatus in the kidneys. The release of renin is 
triggered by a number of physiological stimuli, including PGI2, decreased Na+ 
concentration in the distal tubule, reduced arterial pressure, renal sympathetic nerve 
activation and stimulation of β1- receptors. Following secretion, renin acts upon the 
plasma protein angiotensinogen forming angiotensin I (ang I). Ang I has mild 
vasoconstrictor properties but not enough to cause significant functional changes. 
Ang I is further converted to angiotensin II (ang II) by ACE. Ang II is considered 
the main effector peptide of the renin-angiotensin system (RAAS). Binding of ang 
II to specific receptors activates a number of different events in various tissues and 
cell types. Four types of ang II receptors have been identified; AT1-AT4. Most of 
the cardiovascular effects are generated through the AT1 receptor. Ang II plays an 
important role in blood pressure regulation by inducing arteriolar constriction, 
release of aldosterone from the adrenal medulla and enhanced secretion of 
vasopressin, resulting in increased reabsorption of Na+ and water in the kidneys. 
Ang II also induces several pathophysiological actions involved in the 
atherosclerotic process, such as Proliferation and migration of smooth muscle cells, 
generation of ROS, lipid peroxidation and formation of foam cells. 
            The degradation of ang II by a number of different enzymes occurs only 
seconds after its formation, giving rise to other angiotensin peptides. During the last 
decades, a number of new angiotensin peptides have been identified, and it has 
become evident that RAS is a more complex system than previously thought. Ang 
2-8 acts through the ang II receptors AT1and AT2 and generates similar 
physiological effects as ang II. Ang 3-8 is involved in regulation of blood flow, 
neural development and learning and memory. Ang 1-7 is produced from the 
precursor Ang I and the conversion can be catalyzed by a number of 
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endopeptidases, includingneprilysin and prolyl-oligopeptidase. It is believed that 
ang 1-7 counteracts the effects caused by ang II. Ang 1-7 act through 
specificreceptors (Mas receptors), but have also been reported to activate the AT2 
receptor. Ang 1-7 have antihypertensive, antihypertpophic, antifibrotic and 
antitrombotic properties. In addition, ang 1-7 has been shown to be cardioprotective 
and it has been suggested that ang 1-7 has a role in the protective effect of ACE 
inhibitors (ACEi). 
 
Fig 2: RAAS System 
 
 
 
 
 
 
 
Angiotensin converting enzyme[23] 
ACE is an octo enzyme and glycoprotein with an apparent molecular weight 
of 1,70,000. ACE present in humans contain 1277 amino acid residues and is found 
to have 2 homologous domains, each with a catalytic site and a Zn2+binding region. 
ACE has a large amino terminal extracellular domain, a short carboxyl terminal 
intracellular domain, and a 17 amino acid lipophilic region that binds the octo 
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enzyme to the cell membrane. ACE may lose its C-terminal end and become 
dissolved in plasma as circulating ACE and is found mainly in the lungs due to their 
vast surface of vascular endothelium. ACE is also present in vascular tissues other 
than endothelium; such as smooth muscle cells the heart fibroblasts, the kidney, 
CNS, placenta and testis. ACE is a poly specific enzyme metabolizing angiotensin, 
angiotensin 1-7, enkephalins, substance P and luteinizing hormone-releasing 
hormone (LH-RH). ACE is responsible for at least 90% of the conversion of 
angiotensin I to angiotensin II in the blood, kidney, heart, lung and brain and at least 
77% in the adrenal. 
ANGIOTENSIN CONVERTING ENZYME INHIBITOR[24] 
ACE inhibitors are considered as the most potent antihypertensive drugs and 
apart their major action, exhibit beneficial lateral effects in the prevention of 
cardiovascular disease in various classes of hypertensive patients. Additionally 
ACE inhibitors have been proven more effective than other hypertensive substances 
in reducing protein and urea and retarding the progression of renal damage in 
patients with various types of nephropathy. 
MECHANISM OF ACTION OF ACE INHIBITORS[25] 
All ACE inhibitors share the same mode of action, that is, elimination of the 
production of angiotensin ll inhibition of the degradation of bradykinin. 
Accordingly, all lead to suppression of angiotensin II with 
1) Decrease of blood pressure. 
2)  Vasodilation varying in degree in various tissues (depending on the 
sensitivity of each organ's vascular tree to angiotensin) and leading to 
increase in cardiac output and redistribution of regional blood flows in 
favour of vital organs at the expense of the less-sensitive musculoskeletal 
tissues. 
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3) Partial suppression of aldosterone production by the adrenal zona 
 glomerulosa. 
4) Increase in circulating levels of plasma renin due to interruption of the 
negative feedback control exerted normally by angiotensin II on the release 
of renin. 
5) Potentiation of the vasodilatory effect of bradykinin in sympathetic nervous 
system with diminished levels of plasma catecholamines as well as other 
hormones whose secretion is partly dependent upon the stimulus of 
angiotensin II. 
 
                            Fig 3: Mechanism of ACE inhibition 
 ENZYME ACTIVITY STUDY[26] 
Angiotensin I is a decapeptide which is converted to the pressor of 
octapeptide, angiotensin II, in the presence halide-activated peptidase converted by 
hydrolytic removal of the C-terminal dipeptide, histidyl-leucine. The enzyme 
primarily responsible for the conversion in vivo of circulating angiotensin I to 
angiotensin II was localized in the lung. Existing biological methods for 
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determining the amount of angiotensin I converted to angiotensin II are inadequate 
for assay of the angiotensin converting enzyme in lung extracts or during the early 
stages of purification. 
Angiotensin I is active to some extent in all biological assays in vitro and in 
vivo for angiotensin II; and “angiotensinases” present in all tissue homogenates 
destroy both the octapeptide, for this reason, assay that measured the amount of L-
histidyl-[U-‘4C]-L-leucine formed by the action of the angiotensin converting 
enzyme on synthetic [U-‘4C-Leu’*], [Bes]-angiotensin I’O, and developed an 
automated ninhydrin method that measures the chloride ion-dependent increase in 
ninhydrin- reactive material upon incubation of the enzyme with synthetic-
angiotensin I. 
The possibility of using an assay for angiotensin II to determine the 
angiotensin converting enzyme activity. These assay methods, however, are still 
subjected to errors, due to hydrolysis of both substrates and products by other tissue 
peptidases. Previously reported the activity of angiotensin converting enzyme from 
sheep lungs. 
The C-terminal protected tripeptide, hippuryl-L-histidyl-L-leucine(HHL), 
using a quantitative ninhydrin assay for  detection of liberated hisitdylleucine. The 
histidyl leucine released from other protected tripeptide, Hippuryl-L-histidyl-L-
leucine(HHL). 
In vitro angiotensin converting enzyme inhibitory activity estimates the 
amount of hippuric acid and L-histidyl-L-leucine. Angiotensin converting enzyme 
converts the Hippuryl-L-histidyl-L-leucine (HHL) to hippuric acid and L-histidyl-
L-leucine, and estimate the amount of hippuric acid and L-histidyl-L-leucine by 
spectrophotometry and spectroflourimetry.  
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FLAVONOIDS[27,28] 
Flavonoids represent a diverse group of low molecular weight natural poly 
phenolic compounds. The term Flavonoid has been derived from the latin word 
flavus meaning yellow. Their presence in plant is responsible for various colours 
and combination of colours exhibited by roots, barks, heartwood, leaves, flowers, 
fruits and seeds. In plants, flavonoids occur in different forms, such as free 
aglycones, glycosides, and biflavonoids. Flavonoids function throughout the plant 
kingdom as UV protectants, attract insects for pollination, and antimicrobial 
compounds. Flavonoids and isoflavonoids may be of ecotoxicological importance 
because they are present in the heartwood of tree species used for wood pulp. 
           They are secondary metabolites characterised by flavan nucleus and C6-C8-
C6 carbon-skeleton. These are group of structurally related compounds with a 
chromane-type skelton having phenyl substituent in C2-C3 position. The basic 
structural feature of flavonoid is 2-phenyl-benzo-γ-pyrane nucleus consisting of 
two benzene rings (A and B) linked through a heterocyclic pyran ring (C). The 
flavonoid biosynthesis starts with general phenyl propanoid pathway. It is a very 
complex process and involves series of reactions. 
                                    
 
 
 
 
Fig 4: Structure of flavonoid nucleus 
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Flavonoids have aroused considerable interest because of their potential 
beneficial biochemical and antioxidant effects on human health. Most of the 
experimental results demonstrate that flavonoid compounds have several biological 
activities including radical scavenging, anti-inflammatory, anti-mutagenic, anti-
cancer, anti-HIV and anti-allergic, anti-platelet and anti-oxidant activities. 
Flavonoids are also highly unstable compounds which undergo numerous 
enzymatic and chemical reactions during post-harvest food storage and processing 
thus adding to the complexity of plant polyphenol composition. 
Flavonoids in ACE Inhibition[29,30] 
ACE, a crucial enzyme in the regulation of the renin–angiotensin system, is 
a zinc-containing peptidyl dipeptide hydrolase. The active site of ACE is known to 
consist of three parts: a carboxylate binding functionality such as the guanidinium 
group of arginine, a pocket that accommodates a hydrophobic side chain of  
C-terminal amino acid residues and a zinc ion. The zinc ion coordinates to the 
carbonyl of the penultimate peptide bond of the substrate, whereby the carbonyl 
group becomes polarized and is subjected to a nucleophile attack. Therefore, some 
flavonoids were suggested to show in vitro activity via the generation of chelate 
complexes within the active centre of ACE. Free hydroxyl groups of phenolic 
compounds are also suggested to be important structural moieties to chelate the zinc 
ions, thus inactivating the ACE activity. 
The aim of the present work was to synthesize new flavonoid derivatives in 
order to explore the extent of their angiotensin converting enzyme inhibiting 
activity. The compounds were designed by in silico method using 1o86 (ACE) as 
the target molecule. 
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LITERATURE REVIEW 
CHALCONES 
1) As Angiotensin Converting Enzyme inhibitors 
 S.N.A Bukhari et. al., [31] (2013) synthesized a series of chalcone analogues 
and used as precursor for the synthesis of novel series of pyrimidine and were then 
evaluated for their effect on ACE inhibition. Pyrimidine analogues were found to 
be more active than precursor chalcones. 
O
OH
N
N
R O  
  Macro Bonesi et. al., [32] (2010) synthesized 9 chalcones and their 9 pyrazole 
derivatives and the synthesized compounds were tested for their angiotensin 
converting enzyme inhibiting activity. 
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2)  Antihyperglycemic activity of chalcones: 
 
 Chentana B.Patil et. al., [33] (2009) reported that chalcones have 
hypoglycemic activity. 3,4- dimethoxy chalcone displayed significant 
antihyperglycemic effect. Monomethoxy series showed blood glucose lowering 
activity. Compounds vicinally deoxygenated as dimethoxy and methylene di-oxy 
substituents showed the best antihyperglycemic activity when compared to the 
corresponding monomethoxy compounds. Compounds containing propanolamine 
chain at para position showed significant biological activity as compared to meta 
and ortho substituted compounds.  
 
 Poonam Shukla et. al., [34] (2006) synthesized a series of chalcone based aryl 
oxypropanolamines and tested their antihyperglycemic activity in SLM (Source 
Loaded Model) and STZ (Streptozotocin ) rat models.  
O
O N
OH
CH3
CH3
 
 
 R.S Shinde et. al., [35] (2015) synthesised a series of S-triazine based 
chalcones and the synthesised compounds were studied for their antidiabetic and 
antioxidant activity. 
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3) Chalcones As Antibacterial Agents: 
 
 Y.Rajendra Prasad et. al., [36](2008) synthesized 1-(4’-bromophenyl)-3-(4-
chlorophenyl)-2-propene-1-one and tested antibacterial  activity. 
O
Br Cl
 
 Vishal.D.Joshi et. al., [37](2012) synthesized some novel series of pyrazoline 
derivatives from chalcones. The newly synthesized pyrazoline derivatives were 
screened for anti-microbial activity. 
         
O
O
   
O
N
NH
 
 P.M.Gurubasavaraja Swamy et. al.,[38] (2008) synthesized a series of  
3-hydroxy benzofuran chalcones and the compounds were screened for 
antibacterial activity against Staphylococcus. 
                   
O
OH
CH3
O  
 Paramesh. M et. al.,[39] (2010) synthesized nine Chlorine containing 
chalcones and they were evaluated for antibacterial activity. 
                                                     
Cl
R
O  
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 Rajini Gupta et. al.,[40] (2010) synthesized 1-aryl-3-(4’-chlorophenyl)-prop-
2-en-1-one and tested their antimicrobial activity against Escherichia coli and 
Staphylococcus aureus.  
X
O
Cl
 
X = 4-H, Br, Cl, F, CH3 
 A. Nagaraj et. al.,[41](2008) synthesized bis [3-[(E)-3(4-bromophenyl)-3-
oxo-1-prop-enyl]-4-hydroxy phenyl] methane and tested its anti-bacterial activity. 
  
 O
Br OH OH Br
O  
 Cristina M. Devia et. al., [42](1998) synthesized 2’,4’,2-trihydroxy 
 chalcone and tested its antibacterial activity against Staphylococcus aureus. 
O
OH
OH  
 
4)  Chalcones as Antifungal Agents 
 P.M. Gurubasavaraja swamy et. al., [38](2008) synthesized 1-(3-hydroxy 
benzofuran-2-yl) -3-(4-chlorophenyl)-2-propene-1-one which possesses  very good 
activity against the fungi  Aspergillus flavus. 
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5)  Chalcones as Anti-Oxidants 
 Chentana B.Patil and S.K.Mahajan.,[33] (2009) synthesized 1-phenyl 3-(3,4-
dihydroxy phenyl) propene-1-one which shows antioxidant activity. It was react 
with the radicals and they are readily converted to the phenoxy radicals due to the 
high reactivity of hydroxyl groups of chalcones.  
OH
OH
O  
 Anastasia Detsi et. al., [43] (2009) synthesized  2’-hydroxy –chalcones 
 and  tested  them for their  anti-oxidant activity. 
OOH
X,Y
R2R1
R1
R2
X
X,Y
=
=
=
=
H,OCH3
H,OCH3
OCH3,CH3,Cl
OCH3,OCH2OCH3,OH 
6)  Chalcones as Enzyme Inhibitors 
 Franco chimenti et. al.,[44] (2009) synthesized  4’-benzyloxy chalcones and 
tested them in vitro for their ability to inhibit human monoamine oxidase A and B.  
ClO
O  
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 Woo Duck Seo et. al.,[45] (2005) synthesized  sulfonamide  chalcones   and 
their α-glucosidase inhibitory activities were investigated. 
O
RNHS
O
O
CH3
 
 
7)  Antileishmanial activity of chalcones: 
 
 Carla R. Andrighetti Frohner et. al., [46]  (2008) synthesized 4-methoxy 
chalcone derivatives and tested their potential antileishmanial activity. 
O
OCH3
S
R
O
O
 
R= N(CH3)2 , N(CH3)2 . 
 
8)  Chalcones having anti-tumor activity: 
 Mauricio Cabrera et. al., [47] (2006) synthesized chalcones and tested their 
anti-tumor activity. 
O
yx
z
w  
 Cesar Echeverria et. al., [48] (2009) synthesized 2’-hydroxy chalcones and 
tested them for their anti-cancer activity. 
OOH
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 M.Vijaya Bhaskar Reddy et. al,.[49](2008) synthesized the mannich base of 
heterocyclic chalcone and tested its anticancer activity. 
 
N
OOH
OH
NO
 
 
 Suvitha Syam et. al., [50] (2012)synthesized several chalcones and their  
in vitro cytotoxicity against various human cell lines were evaluated. 
 
O
R
1
R
 
 Visakh Prabhakar et.al., [51] (2014) designed and synthesized a set of mono 
substituted chalcone derivatives and evaluated them for potential cytotoxic activity 
against five human cells. 
 
O
R
R
1
 
 Taran-Thanh-Dao et. al., [52] (2015) synthesized a series of heterocyclic 
chalcones and were evaluated for their cytotoxicity on Rhabdomyosarcoma cell 
line. 
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9)  Anti-inflammatory activity of chalcones: 
 M.S.Y Khan and Sandhya Bawa[53] (2001) synthesized 7-hydroxy-8-[(2E)-
3-(4-methoxyphenyl)prop-2-enoyl]-2H-chromen-2-one and tested its anti-
inflammatory activity. 
 
O
O OOH
H3CO
 
 
 Mazin Nadhim Mousa et. al., [54] (2016) synthesized some chlorinated 
chalcones derivatives and the synthesized compounds were tested for their  anti-
inflammatory activity and were showed comparable anti-inflammatory effect to 
Diclofenac sodium and less than dexamethasone. 
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 Dhanaji H jadhav et. al., [55]  (2007) synthesized a series of twelve 2’,4’-
diflourinated chalcones and subjected to anti-inflammatory activity. 
OF
F
R
 
10)  Antimalarial Activity of Chalcones: 
 Satish.K.awasthi et. al., [56] (2008) synthesised several new chalcone 
analogues and evaluated as inhibitors of chloroquine sensitive Plasmodium 
falciparum strain of parasite. 
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FLAVONOIDS 
1) Angiotensin Converting Enzyme Inhibitory Activity of Flavonoids: 
 Hyuncheol O.H  et. al., [57] (2004) by bioassay-guided fractionation of the 
EtOAc-soluble extract of Sedum sarmentosum afforded a new flavonoid, quercetin-
3-O-α-(6’’’-caffeoylglucosyl-β-1,2-Rhamnoside) along with four known 
flavonoids. All the five compounds exhibited ACE inhibitory activity in a 
concentration dependent manner. 
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 Monica Rosa Loizzo et. al., [58] (2006) extracted six flavonoids from the 
leaves of Alianthus excels and were analysed the in vitro hypotensive activity. All 
the flavonoids tested exhibited ACE inhibiyory activity and the most active 
compound was Kaempferol-3-O-β-galactopyranoside. 
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 B.W Nileeka Balasuriya and H.P Vasantha Rupasinghe[59] (2011) extracted 
apple skin rich in flavonoids and the major constituents of the extract and some of 
the selected metabolites were assessed for the ACE inhibitory property in vitro and 
all the flavonoids tested have a potential to inhibit ACE in vitro and the inhibitory 
property varies according to type of sugar moiety attached at C3 position. 
O
OH
OOH
OH
OH
OH
O
+
OH
OH
OH
OH
 
 
O
OH
OH
OH
O  
 
 Literature Review 
 
 
 
Department of Pharmaceutical Chemistry   36 
 
2) Anti diabetic activity of Flavonoids: 
 Mkunthakumar et. al., [60]  synthesized a series of 2-(2,3,4 and 5 substituted 
phenyl)3-hydroxy-4H-chromen-4-one by reacting 2- hydroxyl acetophenone and 
various aromatic aldehydes and evaluated in vitro anti diabetic activity against 
streptozocin induced diabetic rats. 
O
OH
O
R
1
R
2
R
3
R
4
 
 Yogendra Nayak et. al., [61]  (2014) synthesized 3-hydroxy flavone 
analogues and the compounds are evaluated for their antidiabetic activity in high 
fructose fed insulin resistant rats. 
O
H
R
1
R
2
H
OH
O
R
3
 
 Mahesh Vari Asogan et. al., [62] (2016) synthesized bioactive flavonoid 
derivatives and were screened for their anti-diabetic activity. 
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3) Anti oxidant activity of Flavonoids: 
 Venkatachalam et.al., [63] (2012)  synthesized a series of newer flavones by 
Algar-Flynn-Oyamada method and were evaluated for in vitro antioxidant activity. 
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4) Anti cancer activity of Flavonoids: 
 Jayashree B.S et.al., [64] (2012) synthesized some new substituted flavones 
and screened for in vitro anticancer activity. 
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 Ewelina szliszka et.al., [65]  (2012) synthesized 6-hydroxy flavonone and its 
derivative 6-propionoxy flavonone and the compounds were screened for their anti-
cancer activity. 
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 K.Rajeshbabu et. al., [66] (2016) synthesised various flavonoids under 
autoclave conditions and the compounds were screened for their anti-cancer 
activity. 
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 Mariano Cardemas et. al., [67] (2006) synthesised a series of flavonoids and 
was evaluated in vitro for their antitumor activity. 
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 Lalitha Simon et. al., [68] (2015) synthesised a series of 6-Amino flavones 
and characterised by spectral technique .Their cytotoxic effects have been evaluated 
in vitro in relation to colon HCT116 and breast MCF7 cancer cell lines. 
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 Jing Zhang et.  al., [69] (2013) synthesised chalcones and 5-deoxy flavones 
and they were screened for their cytotoxicity against the cancer cell lines 0f MDA-
MB-231, U251, BGC-823 and B16. 
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5) Anti-microbial activity of Flavonoids: 
 Nazifi Saleh Ibrahim et. al., [70]  (2014) synthesised a series of flavonoids 
and screened for their antibacterial activity against Bacillus cereus, Enterococcus 
faecalis, Klebsiella pneumonia and Pseudomonas aeruginosa and antifungal activity 
against Aspergillus fumigatus, Candida glabrata. All Compounds exhibited activity 
against the entire tested micro organism. 
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 S.S Mokle et al., [71] (2010) synthesised a series of flavones and the 
compounds were evaluated for their antibacterial activity against Xanthomonas 
citri, Ervinia carotovara, Escherichia coli and Bacillus subtilis. 
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 Jayashree B.S et. al., [72] (2008) synthesised different esters of 3-hydroxy 
flavones and the compounds were tested for their activity against Bacillus subtilis, 
Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. 
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 Sohel mostahar et. al., [73] (2007) synthesised a series of flavonoids and the 
synthesised compounds were tested for antibacterial, antifungal and cytotoxic 
activity. 
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 Sayed Alam [74] (2004) synthesised some derivatives of 2-phenyl chromen-
4-one (flavone ring) and tested for antibacterial and antifungal activities along with 
their chalcone precurssors against four human pathogenic bacteria and five plant 
mould fungi. 
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 Sherif B Abdel Ghani et.al., [75] (2008) synthesised flavonoid derivatives 
and evaluated the compounds for their antifungal activity against Aspergillus niger 
and Fusarium oxysporium . 
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6) Anti-Rhinovirus activity of Flavonoids: 
 Clinzia Conti et. al., [76] (2005) synthesised fluro-substituted flavones and 
2-styrylochromones and were tested for anti-rhinovirus activity. The antiviral 
potency was evaluated by a plaque reduction assay in HeLa cell cultures injected 
with rhinoviruses. 
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7) Anti-inflammatory activity of flavonoids: 
 Dharma Theja N et. al., [77] (2001) synthesised a series of flavone derivatives 
and their biological activity was investigated using the model of carrageenan 
induced rat paw oedema. 
O
O
R
R
1
R
2
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 Tuong-Ha Do et. al., [78]  (2009) synthesised a series of flavonoids and 
screened for their anti-inflammatory activity. 
O
O
X
R
1
X
R
2
 
 
 Shrinivas .B.Patil [79] (2013) synthesised substituted 4-benzoyl flavone and 
the synthesised compounds were screened for their  anti-inflammatory, anti-oxidant 
and anti-cancer activity. All compounds showed significant range of activity. 
O
R
R
1
O
O
 
 
8) AChe inhibitory activity of Flavonoids: 
 Rong Sheng et. al., [80] (2009) designed and synthesised a new series of 
flavonoid derivative and evaluatedtheir activity as potent AChe inhibitors. 
R
2
O
O
N
R
1
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9) Peroxynitrite Scavenging activity of Flavonoids:  
 C G M Heijnen et. al., [81] (2001) synthesised a series of flavone for the 
evaluation of peroxynitrite scavenging activity. 
O
O
R
3
R
1
R
2
R
4
R
5
 
 
10) Flavonoids as Amino peptidase N/CD13 inhibitors: 
 Brigitte Bauvois et. al., [82] (2003) synthesised a series of novel flavone -8- 
acetic acid derivatives and were evaluated for their APN/CD13 inhibitory 
activity.2’ 3 di -nitro flavone -8-acetic acid proved to be the most efficient, which 
is two folds active than bestatin, the natural known inhibitor of APN/CD13.  
O
O
O
OH
R
R
1
R
2
R
3
R
4
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CHEMISTRY 
CHALCONE:[33]  
Structure: 
O  
                
  Chalcones are 1, 3-diphenyl-2-propene-1-ones,in which two aromatic rings 
are linked by a three carbon α,β-unsaturated carbonyl system. These are abundant 
in edible plants and are considered to be precursors of flavanoids and isoflavonoids. 
           
Chalcones possess conjugated double bond and a completely delocalized π-
electron system on both benzene rings. The complete delocalization of π electrons 
on both the benzene rings makes these compounds more susceptible in undergoing 
electron transfer reactions .Molecules possessing such systems have relatively low 
redox potentials and have a greater probability of undergoing electron transfer 
reactions. 
 
SYNTHESIS OF CHALCONES 
 Chalcone can be prepared by the reaction between a benzaldehyde and an 
acetophenone in presence of sodium hydroxide or potassium hydroxide as a 
catalyst. 
H
O
+
O
CH3
O
Base
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Synthesis of 2’, 4’, 2-trihydroxy chalcone:[83] 
            2’, 4’,2-trihydroxy chalcone was prepared by adding KOH to an equimolar 
solution of aldehyde and ketone solution in ethyl alcohol .  
H
O
+
O
CH3 Base
O
OH
OH OH
 
Synthesis of 1-(4’-bromophenyl)-3-(4-chlorophenyl)-2-propen-1-one:[36] 
            1-(4’-bromophenyl) -3- (4-chlorophenyl) -2- propen-1-one was synthesised 
by the reaction of 4’-bromo acetophenone and 4-chloro benzaldehyde in the 
presence of KOH . 
 
O
CH3
Br
+
OHC
Cl
O
Br Cl
KOH
Room temp,
24hrs
 
Synthesis of chalcones based on the Suzuki reaction:[84] 
Synthesis of chalcones based on the Suzuki reaction either between 
cinnamoyl chlorides and phenyl boronic acids or between benzoyl chlorides and 
phenyl vinyl boronic acids are described. 
Ph
B
OH
OH
+
Cl
O
Ph
Ph
O
Cl OH
B
OH
Ph
+ Pd
2+
(or)
Pathway A Pathway B
O
Chalcone
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Synthesis of chalcones in the presence of potassium phosphate:[85] 
            Chalcones are synthesised by the reaction of aldehydes and ketones from 
the presence of potassium phosphate. 
R
CHO
+ R'
Me
O O
R' R
K3PO4,EtOH
R= H,OH
R= H,OH'
 
REACTIONS   OF CHALCONES  
Formation of 3-(4-methoxyphenyl)ethyl 2-acetyl-5-oxo-3,5-
diphenylpentanoate:[86] 
              4-methoxy chalcone reacts with ethylacetoacetate in presence of 
potassium suproxide,tetraethylammonium bromide and dry DMF(dimethyl 
formamide) to form 3-(4-methoxyphenyl)ethyl 2-acetyl-5-oxo-3,5-
diphenylpentanoate. 
 
MeOC CO2Et
O
MeO
MeCOCH2CO2Et
O
MeO
KO2 Et4Br
DMF(Dry)
 
MeOC CO2Et
O
MeO
MeCOCH2CO2Et
O
MeO
KO2 Et4Br
DMF(Dry)
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Mechanochemical reactions of chalcones:[87] 
 
 Chalcones react with ethylacetoacetate catalysed by K2CO3 under solvent 
free condition. 
X
O
Ar
-
CH3COCH2COOEt
K2CO3CO.(equiv)
HSVM
X
O
CH3
O
EtOOC
Ar
-
+
X
O
CH3
O
EtOOC
Ar
-
 
 
Formation of dihydropyrimidine under ultrasound irradiation:[88] 
 
             Chalcones reacted with urea in presence of potassium hydroxide in ethanol 
to produce  4,6-(diphenyl)-3,4-dihydropyrimidine-2(1H)-one under ultrasound 
irradiation. 
OOH
+
NH2 NH2
O
KOH
EtOH
NH NH
O
 
 
OOH
+
NH2 NH2
O
KOH
EtOH
NH NH
O  
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Formation of cyclohexanone derivative:[89] 
          Chalcone react with cyclohexanone in presence of potassium hydroxide to 
form 2-(3-oxo-1,3-diphenylpropyl cyclohexanone . 
O
+
O
%6KOH
3to4hrs
O O
 
Reactions of chalcones with N-bromo succinamide:[90] 
 Chalcones react with N-bromo succinamide to form dibromo chalcones . 
O
OH R
1
O
Br
Br
OH R
1
 
 
Formation of substituted but-3-ene-1,2-diol:[91] 
              Chalcones and aldehydes react together to form but-3-ene-1,2-diol in the 
presence of indium/indium trichloride in aqueous media. 
CHO
R3
R2
R1
+
R5
O
R4
i
OH
R5
OH
R2
R3R1
R4R3
R4
R5
R2
R1 =
=
=
=
=
H,OCH3
H,OCH3
H,OCH3
H,OH
H,phenyl
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Hydrocyanation of chalcones with trimethyl silyl cyanide:[92] 
               β-cyanoketones are formed by the reaction of chalcones with trimethyl 
silyl cyanide (TMSCN) . 
O
R2
R1
O CN
R1
R2
i )TMSCN
microwave
THF
R1= H
R2= OH
Formation of 3-benzimidazolyl-5-aryl-2-pyrazole:[93] 
             The reaction of benzimidazolyl chalcone with bromine in chloroform gave 
dibromochalcone which underwent condensation with hydrazine hydrate to form 
3-benzimidazolyl-5-aryl-2-pyrazole . 
 
N
N
H
O
Ar
-
Br2
CHCl3/R.T
Benzimidazolyl 
chalcone
N
N
H
O
Ar
-
Br
Br
N
N
H
N
H
N
CH3
Benzimidazolyl chalcone 
dibromide
NH2NH2.H2O
3-Benzimidazolyl-5 -aryl -2 -
pyrazole
 
Preparation of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole:[94] 
 Chalcones condensed with thiosemicarbazide in ethanol and KOH under 
ultrasound irradiation to form 1-Thio carbomyl-3,5-diphenyl-4,5-dihydro-1H-
pyrazole . 
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Formation of 2-(4-bromonaphthalene-1-yl)-6-chloro-chromen-4-one:[95] 
 It was formed by the reaction of chalcone with DMSO (dimethyl 
sulphoxide) and iodine. 
OH
O
CH3
Cl
+
CH3
Br
O
EtOH
10%KOH
Br
OH
OCl
Br
O
OCl
DMSO/I2
 
 
Formation of flavone from chalcone-2’-ol:[96] 
            Chalcone react with DMSO (dimethyl sulphoxide) and Iodine under 
microwave condition to form flavones. 
O
OH
Microwave
DMSO/I2 O
CH3
 
Formation of pyrimidine by microwave irradiation of chalcones:[97] 
            Benzofuro-3-aryl prop-2-en-1-one is react with guanidine hydrochloride by 
microwave irradiation to form 6-(1-benzofuran-2-yl)-4-phenyl-4,5-
dihydropyrimidin-2-amine . 
O
O
NH2
NH2
NH
HCl
Microwave NaOH
O
N
N
NH2
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Formation of pyrazole from chalcone dibromide:[98]  
Chalcone dibromide react with phenylhydrazine and TEA 
(Triethanolamine) to form pyrazole. 
O
OH
CH3
OCH3
TEA
Phenyl hydrazine
CH3
OH
N
N
OCH3
 
Formation of 3-(2’-hydroxy-4’-benzyloxy phenyl)-5-phenyl pyrazole from 
chalcone:[99] 
             Chalcone reacts with hydrazine hydrate and methanol to form 3-(2’-
hydroxy-4’-benzyl oxy phenyl)-5-phenyl pyrazole. 
 
O
OHPhH2CO
OHPhH2CO
N NH
NH2NH2.H2O
MeOH
 
Formation of pyrimidine from chalcone:[100] 
              Chalcone reacts with urea to form pyrimidine. 
CH3 OH
O
NH2-CO-NH2
NN
OH
OHCH3
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FLAVONOIDS [101] 
                                     
 Flavonoids consist of a large group of polyphenolic compounds 
having a benzo-𝛾-pyrone structure and are ubiquitously present in plants. 
Their basic structure is a skeleton of Diphenyl propane, namely two benzene 
rings linked by a three carbon chain that forms a closed pyran ring. 
Therefore, their structure is also referred to as C6-C3-C. . They are 
synthesized by phenylpropanoid pathway. Chemical nature of flavonoids 
depends on their structural class, degree of hydroxylation, other 
substitutions and conjugations, and degree of polymerization .According to 
the IUPAC nomenclature, they can be classified into: 
 isoflavonoids, derived from 3-phenylchromen-4-one (3-phenyl-1,4-
 benzopyrone)      structure 
 neoflavonoids Flavonoids or bioflavonoids 
 derived from 4-phenylcoumarine (4-phenyl-1,2-benzopyrone) structure  
Flavonoids have ability to induce human protective enzyme systems. The 
number of studies has suggested protective effects of flavonoids against many 
infectious (bacterial and viral diseases) and degenerative diseases such as 
cardiovascular diseases, cancers, and other age-related diseases.   
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 SYNTHESIS OF FLAVONOIDS 
Synthesis of flavonoids via Heck reaction [102] 
Synthesis of flavonoids can be achieved by using the Heck reaction.  The 
key step involves the coupling of an aryl vinyl ketone with an aryl iodide. This 
procedure affords the flavonoid moiety in a single step. 
CH3
O
O
CH3
CH2
O
+
Pd(OAc)
2
, PH
3
P
CH
3
CN, Et
3
N
O
O
CH3
CH3
OAcOAc
I
O
O
O
CH3
OH
 
Allan-Robinson synthesis of flavonoids [103] 
Allan-Robinson synthesis involves reaction of 2′-hydroxyacetophenone and 
benzoic acid anhydride in hot pyridine to give a 1, 3-diketone as the key 
intermediate and subsequent cyclisation in acidic medium gave the flavones. 
OHOH
OH
CH3
O
+
O
O O
pyridine 
reflux
OHOH
O O
pyridine
reflux
O
O
OH
OH
Synthesis of flavonoids via intra molecular Wittig reaction [103] 
Acylation of the acetophenone with benzoyl chloride followed by reaction 
with bromine triphenylphosphine gives the corresponding phosphonium bromide, 
which then undergoes ring closure via intramolecular olefination of ester carbonyl 
group to afford the flavone. 
OH
CH3
O
+ Cl
O
O
O
CH3
O
P
+
(Ph3)Br
O
O
O
O
O
pyridine PPh3
Br
2
Na
2
CO
3
CH
2
Cl
2
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Auwers flavone synthesis [104] 
The Auwers flavones synthesis involves treatment of a dibromoaurone with 
alcoholic alkali to give 3-hydroxyflavone. 
O
O
Br
Br
KOH, EtOH
Reflux
O
O
OH
 
 
Synthesis of flavonoids by Sonogashira-Carbonylation-Annulation  
reaction [105] 
This method involves the synthesis of flavones via the Pd catalyzed 
Sonogashira-Carbonylation-Annulation reaction between 2-iodophenols and 
terminal alkynes. 
O
I
CH3
+
H
TMS
Pd
2
(dba)
3
/PA-PH
DMF, DBU
 MW, 30 min
O
CH3
TMS
OH
I
Pd
2
(dba)
3
/PA-PH
1atm CO
TBAF,DMF,DBU
MW, 30min
O
O
O
CH3
 
 
Synthesis of 3[4’-Dimethylamino] benzoyl-6-methyl-2[4’-dimethylamino] 
phenyl-2,3-dihydro- 4H-chromen-4-one,  (substituted 3-benzoyl flavone)  by 
modified  Baker-Venkatraman Reaction [79] 
 
Synthesis of 3[4’-Dimethylamino] benzoyl-6-methyl-2[4’-dimethylamino] 
phenyl-2,3-dihydro- 4H-chromen-4-one was synthesised by the reaction of 5-
methyl-2-hydroxy acetophenone and p-N,N-dimethylamino benzoyl chloride in 
presence of K2CO3.  
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OH
CH3
CH3
O
2+ Cl
O
N
CH3
CH3 K2CO3
Dry acetone, Reflux
O
O
N
CH3
CH3
N
CH3 CH3
CH3
O
5-methyl-2-hydroxy 
acetophenone
p-N,N-dimethylamino 
benzoyl chloride
Synthesis of Flavonoid using ionic liquid catalyst [106] 
Substituted α-β-unsaturated carbonyl compounds which are chalcones  are 
converted to corresponding substituted 2-phenylchroman-4-one i.e. flavanone by 
grinding at room temperature using ionic liquid catalyst, H [bimBF4]. 
O
O
O
R
1
R
2
R1
R2
H[bimBF4]
 
Solvent-Free Synthesis of Functionalized Flavones under Microwave 
Irradiation [107] 
It involves the direct solvent-free synthesis of flavones is achieved by 
microwave irradiation of phloroglucinol and β-ketoesters. The reaction goes 
through a cycloaddition of an α-Oxo ketene intermediate followed by an 
uncatalyzed thermal Fries rearrangement. 
OH
OH
OH
+
O OR1
R2
R3
R4
OEt
MW
OH
OH
O
O
R4
R3
R2
R1
phloroglucinol
-keto esters
flavone
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An efficient one-pot synthesis of flavones [108] 
2’-hydroxy acetophenone was treated with 3 equivalents of aroyl chloride 
in wet K2CO/acetone to afford a good yield of flavone and a smaller yield of 3-
aroyl flavone. The reaction proceeds via triketone intermediate. 
 
CH3
O
OH
p- R4C6COCl
(3 equiv)
K2CO3, wet acetone
reflux
O
O
+
R1
R3
R2 R2
R3
R4 R4
R4
R2
R1
R3
R1 O
O
2'-hydroxyacetophenone
                  flavone
            (major product) 3-aroylflavone
 
Synthesis of flavone via a Houben-Hoesch reaction [103] 
Coupling of phloroglucinol and 3-phenyl-2-propynenitrile to afford an aryl 
ethynylketone, which was cyclised in aqueous piperidine to give flavone. 
OHOH
OH
+
N
HCl(g), ZnCl
2
10%HCl, Refux
OHOH
OH O
5%piperidine aq
O
O
OH
OH
FlavoneAryl ethynyl ketone3-phenyl-2propyne nitrilePhloroglucinol
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REACTIONS OF FLAVONOIDS 
The chemistry of flavones is quite simple and a variety of reactions occur 
depending on the reagents used and the functional groups present. In general, they 
possess three functional groups viz. hydroxyl, carbonyl, and conjugated double 
bond; hence they give characteristic reactions of all three functional groups. 
 
Degradation in presence of base[103] 
The structure of flavones is determined mainly by identification of alkaline 
degradation products. Degradation by using anhydrous ethanolic KOH and aqueous 
KOH cleaves the molecules in two different ways. 
a)         
O
O
O O
OH
OH
O
+
CH3
O
aq.KOH
 
b)  
O
O
O O
OH
CH3
O
+
OH
O
anhy.ethanolic
KOH
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Reduction Reactions [103] 
Catalytic Reduction 
a) Flavones on reduction with Adam’s catalyst, the 2,3-olefenic bond is 
 reduced to yield flavonone. 
O
O
Adams catalyst
O
O  
b) Structure of flavone is interrupted after the absorption of 3 mole of 
hydrogen in presence of platinum, resulting in the reduction of B ring. 
 
O
O
O
O
PT
H
2
 (3mols)
 
 
Reduction with Lithium Aluminium Hydride 
Uncontrolled reduction of flavone will occur with Lithium Aluminium 
Hydride to yield flavenes. 
O
O
LiAlH
4
O
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Shinoda test 
In this keto group of the C ring is reduced with a shift in the bonds on that 
part of the ring, resulting in the formation of flavylium ion. 
O
O
Mg/HCl O
+
 
 
Oxidation reactions[103] 
3’,4’,5,6’,7-penta methoxy flavone is oxidised with silver 0xide and Nitric 
acid, only the methoxy group at 1,4 orientations are oxidised leading to the 
formation of a quinoline intermediate, which is a diel’s alder adduct with butadiene. 
 
O
O
H3CO
OCH3
OCH3
OCH3
OCH3
AgO,6 N HNO3
Acetone
Dioxane
O
O
H3CO
OCH3
OCH3
O
O
CH2
CH3
CH2
CH3
O
O
H3CO
OCH3
CH3
CH3
O
O
OCH3
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Reaction with electrophiles 
a) Chloromethylation 
Chloromethylation occurs at C3 position by the reaction with formaldehyde 
in the presence of HCl or Acetic acid with ZnCl2. 
O
O
CH
2
O/HCl
ACOH/ZnCl
2
O
O
CH2Cl
 
b) Bromination 
Reaction with bromine in the presence of excess of AlCl3 yields bromo 
flavone. 
O
O
Br
2
/AlCl
3
O
Br
O
 
c) Sulphonation 
Sulphonation of flavone with chlorosulphonic acid at 1000C yields the 6-
sulphonylderivative, but at 130-1400C a second substituent is introduced to give 
3,6-disulphonyl chloride. 
O
O
O
O
ClO3S
O
O
ClO3S SO3Cl
ClSO
3
H
1000C
ClSO
3
H
1600C
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d) Nitration 
Nitration occurs when flavone reacts with conc.HNO3 at 100°C. It occurs 
mainly at C6 position. 
O
O
O
O
N
+O
-
O
HNO
3
100 0C
 
e) Mannich reaction 
This is a multi-component condensation which involves an enolizable 
carbonyl compound, formaldehyde and a primary or secondary amine, resulting in 
the formation of a mannich base. 
O
O
OH
+
O
H H
+ R -H
DMF,ethanol
OOH
O
R
R- any 10 or 20 amino compound
 
 
Reaction with Carbon nucleophiles[109] 
Reaction with Grignard reagent 
Grignard reagent reacts with flavone at the carbonyl carbon resulting in 
flavonols and can be converted by acidinto the corresponding 4-substituted 1-
benzopyrylium salt. 
O
O
PhMgBr O
OH Ph
HCl O
+
Ph
Cl
-
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Reaction with Organometallic reagents 
Flavone can be lithiated at C3. 
O
O
THF,-78 0C
LDA
51%
(EtO)
2
C=O
O
O
CO2Et
Addition/Condensation reactions [103] 
a) Reaction with hydroxylamine 
Flavone on reaction with hydroxylamine yields phenyl-isoxazoles instead 
of expected oximes. This is due to the mesomeric effect of phenyl group as well as 
the existence of the non-canonical resonance form. 
O
O
OH -NH
2
O
O
-
OH
-
 NH2
+
OH
O N
 
b) 1,4-dipolar addition to flavone 
Flavone condenses with 9-fluoro enyl sodium to give the 1,4-addition 
product 2-hydroxy-β-fluorenylidene-β-phenyl-1-propiophenone. 
O
O
-      Na
+
Ph
O
OH
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Substitution Reaction 
Flavone with reagents like pyridine hydrobromide per bromide (PHPB) 
without using mercury salts forms substituted product. 
O
O
PHPB O
O
Br
 
Ring Contraction Reactions [110] 
a) Reaction with iodine 
Reaction of flavonone with Iodine results in the formation of a mixture of 3 
products-dihydro benzofuran derivative,3-methoxy flavone and flavones. 
 
O
O
O
COOMe
+
O
O
OMe
+
O
O
I2
 
b) Carbon monoxide elimination reaction 
In some special conditions elimination of carbon monoxide from flavonoids 
will results in a ring contraction product. 
O
O
OH
O
OH
-CO
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Photochemical Reactions [111] 
a) Photo tautomerization reaction 
Flavonoids undergo photo tautomerism by the interconversion of isomeric 
forms in equilibrium by the migration of hydrogen atom. 
O
O
O
H
O
+
OH
O
-
heOH
 
b) Photo rearrangement Reaction 
3-hydroxy flavone undergo photo rearrangement leading to the formation 
of indan-1,2-diones. 
O
OH
O
h
O
O
OH
 
c) Photo oxidation Reaction 
Photo oxidation of 3-hydroxy flavone has been found to yield mixture of 
two products two products through the reorganization and degradation. 
O
O
OH
h/O2
O
O
O
H
O2
-CO2
O
O
OH
O
OH2
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d) Photoreduction Reaction 
Photochemical reduction of flavones results in the formation of two 
products which were obtained by the reduction of  2,3 double bond and >C=O 
group. 
O
O
O
O
H
H
+
O
OH H
h
MeOH/HCl
e) Photoinduced H- abstraction 
Phototransformation of3-alkoxy flavones resulted in the formation of a 
tetracyclic compound instead of a ring contracted product,which could be ascribed 
from the intramolecular H-abstraction by photoexcited C=O group. 
O
O
O
CH3
h
O
OO
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OBJECTIVE OF THE STUDY 
 
High blood pressure or hypertension is a major cause of morbidity and 
mortality because of its association with coronary heart disease, cerebrovascular 
disease and renal disease. The extent of target organ involvement (i.e. heart, brain 
and kidneys) determines outcome. Worldwide, hypertension is estimated to cause 
7.5 million deaths, about 12.8% of the total of all deaths and this also accounts for 
57 million disability adjusted life years (DALYS) or 3.7% of total DALYS. The 
increasing prevalence of the condition is blamed on lifestyle and dietary factors 
such as physical inactivity, alcohol and tobacco use and a diet high in sodium.  
Angiotensin Converting Enzyme (ACE), the central component of the 
Renin-Angiotensin System (RAS) controls the blood pressure by regulating the 
volume of fluids in the body. It converts the hormone angiotensin 1 to the 
angiotensin ll. Therefore ACE indirectly increases blood pressure by causing blood 
vessels to constrict. 
The inhibition of ACE is considered as one of the most effective therapeutic 
strategy for the treatment of Hypertension. Enzyme inhibitors are used as potent 
therapeutic agents for the treatment of various diseases. More than 100 drugs used 
worldwide are enzyme inhibitors. ACE inhibitors such as captopril, enalapril, 
fosinopril and ramepril currently available in the market; exert antihypertensive 
effect by competitively binding to the active site of ACE. 
Flavonoids are fairly versatile compounds and are easy to synthesize. They 
are associated with a wide range of pharmacological properties including 
antimicrobial, antioxidant, anticancer, anti-inflammatory activities. In addition, 
literature review also revealed that flavonoids possess ACE inhibitory activity.  
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The present study focuses on the development of certain flavonoid 
derivatives in order to explore the extent of their antihypertensive property and to 
identify the correct conformations of ligands in the active site of protein and to 
predict the affinity of the ligands towards the protein.  Drug discovery tools have 
been utilized in designing new chemical entities which are safe and effective 
without consuming much of the research hours. 
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PLAN OF WORK 
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EXPERIMENTAL SECTION 
 
IN SILICO STUDIES  
 
Softwares and Databases used  
 Accerlys discovery studio viewer  
 Molinspiration server  
 RCSB protein data bank  
 Online SMILES translator  
 Autodock 4.2 which combines  
 Autodock tools  
 Python molecule viewer 1.5.6  
 Vision 1.5.6  
 Cygwin 64  
 
TARGET SELECTION 
 The present study was focused on antihypertensive activity and the target 
 selected for the work is Angiotensin converting enzyme (1o86).  
 Based on various literature reviews and current researches, the active 
 binding sites required for exhibiting antihypertensive activity was 
 obtained. 
 The pdb structure of the target enzyme is downloaded from RCSB protein 
 data bank. 
 
SELECTION OF LEAD 
The lead compound flavonoid was selected based on several literature 
reviews. Many flavonoid derivatives were reported to have ACE inhibiting 
activity. 
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LEAD OPTIMIZATION 
The lead moiety selected was optimized by substituting specific groups in 
order to enhance the safety and efficacy of the compounds. This process was 
performed by evaluating pharmacokinetic property of the compound. Toxicity 
studies are performed by the evaluation of drug likeness properties.  
 
Evaluation of drug likeness properties[112] 
For the better oral absorption of the ligands the drug likeness scores are 
constructed by getting information about the solubility, diffusion, Log P, 
molecular weight etc., one of the ideal methods for this is using Lipinski’s rule of 
five with the molinspiration server. 
 
Calculation of Lipinski’s rule of five 
1. Open the molinspiration home page. 
2. Click calculation of molecular properties of drug likeness 
3. Draw the structure of SB I in JME window. 
4. Click calculate properties. 
5.  Save the properties 
 
Rests of the compounds are observed in the same manner. 
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RESULTS AND DISCUSSION 
 
Drug likeness scores of SB 1-5 
Table 1.   Drug likeness scores of SB 1-5 using Molinspiration 
Sl. No 
Compound 
Code 
Log P 
Molecular 
Weight 
Hydrogen 
acceptors 
Hydrogen 
donors 
No. of 
Violations 
1 SB1 3.78 403.39 7 3 0 
2 SB2 4.20 432.39 9 2 0 
3 SB3 4.05 415.40 7 2 0 
4 SB4 4.94 421.84 6 2 0 
5 SB5 3.60 433.42 8 3 0 
 
Drug likeness scores of BF1-5 
Table 2. Drug likeness scores of BF 1-5 using molinspiration 
Sl. No 
Compound 
code 
Log P 
Molecular 
Weight 
Hydrogen 
acceptors 
Hydrogen 
donors 
No. of 
Violations 
1 BF1 4.49 432.34 10 1 0 
2 BF2 3.88 522.11 10 1 1 
3 BF3 5.88 411.24 4 1 1 
4 BF4 4.68 402.40 6 1 0 
5 BF5 7.18 480.13 4 1 1 
 
In vivo absorption abilities of the designed molecules were assessed by 
means of Lipinski’s rule of five that predicts a compound administered orally will 
more likely to have a good absorption or permeation. Most of the designed 
compounds satisfy the rule; some shows violation. This indicates that all the 
ligands SB 1-5 and BF1-5 have good oral absorption. 
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DOCKING STUDIES FOR THE LEAD 
Aim   :  To predict the bioactivity score of the ligand 
Database  :  RCSB protein data bank 
Protein selected :  Angiotensin Converting Enzyme (1o86) 
 
Target proteins were downloaded from RCSB protein data bank and 
docking studies were performed. 
 
Steps involved in docking studies [113-115]  
Running docking process with AutoDock 4.2 
 Conversion of refined enzyme into .pdb format. 
 Conversion of pdb format of ligand into .pdbqt format 
 Preparation of grid box by setting grid parameters 
 Docking process  by setting docking parameters 
 Docked result from .dlg file 
 Viewing docked confirmation 
 Taking snapshots of the interactions. 
 
STEP1: 
Refinement of protein structure  
 Protein (1o86) downloaded from protein data bank and it was refined 
before docking. Refinement of downloaded protein involves the removal of water, 
hetero atoms and bound ligands if any.  
The steps involved are 
1.  Open Accerlys discovery studio viewer. 
2.  File → open → Protein (downloaded from PDB). 
3.  View→ Hierarchy. 
4.  Click water molecules. 
5.  Select all water molecules. 
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6.  Give right click and cut. 
7.  Select ligand, give right click and cut. 
8.  Save the molecule in desired area. 
The 1o86.pdb is refined by the above method. 
 
STEP 2: 
Ligand File Format Conversion: 
1. The ligands SB 1-5 and BF 1-5 are drawn in chemsketch software. 
2. Tools→ Generate →SMILES notation [Simplified Molecular Input Line 
 Entry System, which is a file format] 
3. Save the SMILES in a word document. 
4. Open the online smiles translator  
5. Upload the SMILES. 
6. By choosing the required file format we can save the file. 
    Here, we are saving it as .pdb format in Cygwin/usr/local/bin. The protein 
and ligand files which are prepared by above methods were used for docking. 
 
STEP 3: 
DOCKING 
Docking was performed using AutoDock 4.2 and requires a refined 
protein and ligands in .pdbqt format. 
Steps involved are as follows; 
 
Conversion of refined protein to protein.pdb  
Open   Auto dock tool 
 Open  Read molecule Refined Enzyme (1o86)                
 Select  Select from string  Type(*HOH)  add   
  dismiss 
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 Edit  Hydrogen Add Ok 
 Edit  Charges Add Kollman Charges Ok 
 File Save Write  PDB Cygwin/usr/local/bin
 Ok 
 Edit Delete all molecules Continue. 
 Refined proteins were converted to pdb format and saved as1086.pdb in 
folder bin in Cygwin. 
 
Conversion of PDB format of ligand into .pdbqt format 
Algorithm: 
 Ligand Input Open (SB I.pdb ) 
 Ligand Torsion tree Detect root 
 Ligand Torsion tree Show root expansion 
 Ligand Torsion tree Choose torsion 
 Ligand Torsion tree Set no. of torsion 
 Ligand Torsion tree Hide root expansion 
 Ligand Torsion tree Show hide root marker 
 Ligand Output Cygwin as (SB I.pdbqt) in 
 Cygwin/usr/local/bin 
 Edit  Delete all molecules Continue 
 SB I.pdb was converted to SB I.pdbqt, which is the software acceptable 
form. Other ligands are done by the same method. 
Autogrid Calculation and creating ‘gpf’ file 
Algorithm: 
 Grid Macromolecule Open
 protein.pdbqt(1086.pdbqt) 
 Grid Set map types Open Ligand.pdbqt (SB 
 I.pdbqt) 
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 Grid Grid box dimensions to 60 Close saving 
 current. 
 Grid Output Save as gpf SB I.gpf in  
 cygwin/usr/local/bin  
 
Autodock calculations and creating ‘dpf’ file 
Algorithm: 
 Docking Macromolecules Set rigid file name  
 protein.pdbqt (1o86.pdbqt) 
 Docking ligand ligand.pdbqt (SBI.pdbqt) 
 Docking Search parameters Genetic algorithm
 Accept 
 Docking Docking parameters Accept 
 Docking Output Lamarckian GA(4.2) SB I. dpf in  
 cygwin/usr/local/bin 
 
Programming of ‘AutoGrid’ and ‘Auto Dock’ execution: 
 Open Cygwin terminal  
cd C: 
cd Cygwin 
cd usr 
cd local 
cd bin 
Program should list out the pdb,pddbqt, gpf and dpf files of an enzyme and 
ligand. 
 /autogrid4.exe  –p  SBI.gpf   -l  SBI.glg 
The resulting file was obtained in .glg format  
 
 Experimental Section 
 
 
 
Department of Pharmaceutical Chemistry   76 
 
 /autodock4.exe  -p  SBI.gpf  -l  SBI.dlg 
 The resulting file was obtained in .dlg format 
STEP 4: 
Viewing docking results 
Algorithm 
 To open dlg file  
 Analyze Docking ligand.dlg (SBI.pdbqt) 
 To obtain binding energy    
 Analyze Confirmation load  
Thus the binding energy of 10 docked confirmations of the ligands was 
obtained. Software automatically ranks the energy values in the order of 
increasing binding energy. 
 Visualizing docked conformations & Obtaining snap shots of docked 
 pose 
 Analyze → Conformations → Play (Note: & allows changing the ligand's 
 color). 
 Load SBI.dlg file. 
 Choose the conformation. 
 Analyze → Macromolecule → choose the 1o86.pdbqt. 
 Analyze → Conformations → Load [double click the desired 
 conformation]. 
 Analyze → Dockings → Open. 
 Analyze → Dockings →Show interactions. 
 Protein and ligand interaction will be displayed. Zoom it and increase the 
 contrast by holding right key & shift. 
 File → save image → Cygwin/usr/local/bin as .jpeg 
The steps above mentioned are done for all the 10 ligands (SB1-SB5 and 
BF1-BF5) 
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RESULTS AND DISCUSSIONS 
 
  The docking results of ACE (1o86.pdb) with the ligands SB1-5, BF 1-5 
and Standard drug Lisinopril are reported in the below tables. The best docked 
structures should have the binding energy lower to the standard. The binding sites 
are shown in the snapshots and the binding energy compared with the standard 
drug is given in the table 3 and 4. 
Binding energies of SB 1-5 with ACE 
Table 3: Binding energies of SB 1-5 
Sl.No Compound Code Binding Energy Kcal/mol 
1 SB 1 -9.39 
2 SB 2 -12.29 
3 SB 3 -9.47 
4 SB 4 -9.56 
5 SB 5 -6.49 
6 Lisinopril (LIS) -7.75 
 
Binding energies of BF 1-5 with ACE 
Table 4: Binding energies of BF 1-5 
Sl.No COMPOUND CODE 
BINDING ENERGY 
Kcal/mol 
1 BF 1 -5.06 
2 BF2 -4.58 
3 BF3 -8.11 
4 BF4 -6.64 
5 BF5 -8.63 
6 Lisinopril (LIS) -7.75 
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In the Schiff bases of flavonoid series (SB1-5), all the ligands except SB5 
showed excellent binding interactions with the ACE. Among the derivatives SB2 
had shown highest binding energy (-12.29 Kcal/mol) when compared to the 
standard drug Lisinopril (-7.75 Kcal/mol).The order of binding energy was found 
to be in the order SB2 (3-nitro) > SB4 (4-chloro)> SB3 (4-formyl) > SB1 (4-
hydroxy) > SB5 (4-hydroxy-3-methoxy). 
 
In the substituted benzoyl flavone series (BF1-5), the ligand BF5 (-8.63) 
showed highest interaction with the enzyme. The order of binding energy of these 
compounds was found to be BF5 (2,4-dichloro) > BF3 (2-chloro) > BF4 (3-
methoxy) > BF1(3-nitro) > BF2 (3,4,5-trimethoxy). 
 
The ligands SB2, SB4, SB3, SB1, BF5, BF3 shown best docked pose to 
enzyme (1o86).These ligands can be screened for the activity. Though some 
ligands showed inferior binding interactions, all the selected derivatives were 
planned to synthesize and to screen for the ACE inhibiting activity. 
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Binding of lisinopril with ACE 
Lisinopril interacts with ACE at GLY 2000, GLU 384, LYS 511, ALA 
354,PHE 512, HIS 353,  GLU411,TYR 523,ARG 522 and the binding energy was 
found to be -7.75 Kc/mol. 
 
Fig 5: Snapshot of lisinopril binding with 1o86  
Binding of SB1-5 with ACE 
SB1 
SB1 interacts with ACE at ALA 354,GLY 2000,SER 255 and HIS353 and 
the binding energy was found to be -9.39Kcal/mol 
 
                            Fig 6: Snapshot of SB1 binding with 1o86 
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SB2 
SB2 interacts with GLY 2000, HIS 353 ,SER 355,TYR 523 and ALA 354 
and the binding energy was found to be -12.29Kcal/mol. 
 
Fig 7: Snapshot of SB2 binding with 1o86 
SB3 
SB3 binds with ACE at ALA 354,GLY 2000,TYR 523 and SER 355 and 
the binding energy was found to be  -9.47Kcal/mol. 
 
 
Fig 8: Snapshot of SB3 Binding with 1o86 
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SB4 
SB4 interacts with ACE at GLY2000,ALA 354, HIS 353, PHE 512,TYR 
523 and SER 355 and the binding energy was found to be -9.56Kcal/mol. 
 
Fig 9: Snapshot of SB4 binding with 1o86 
 
SB5 
SB5 interacts with ACE at GLY 2000, ALA 354, TYR 523,PHE 512, 
GLU 411 and LYS 511 and the binding energy was found to be -6.49Kcal/mol. 
 
Fig 10: Snapshot of SB5 binding with 1o86 
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Binding of BF1-5 with ACE 
BF1 
BF1 interacts with ACE at GLY 2000,TYR 523, HIS 353 and ALA 354 
and the binding energy was found to be -5.06Kcal/mol. 
 
Fig 11: Snapshot of BF1 binding with 1o86 
BF2 
BF2 interacts with ACE at HIS 353, ALA 354, GLU 384, TYR 523, VAL 
518 and ARG 522 and the binding energy was found to be -4.58 Kcal/mol. 
 
 
Fig 12: Snapshot of BF2 binding with 1o86 
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BF3 
BF3 interacts with ACE at HIS 353, ALA 354, TYR 523, GLY 2000 and 
GLU 384 and the binding energy was found to be -8.11Kcal/mol. 
 
 
Fig 13: Snapshot of BF3 binding with 1o86 
 
BF4 
BF4 interacts with ACE at ALA 354, HIS 383, ALA 354 and GLU 384 
and the binding energy was found to be -6.64 
 
Fig 14: Snapshot of BF4 binding with 1o86 
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BF5 
BF5 reacts with ACE at GLU 384, GLY2000, TYR 523 and HIS 353 and 
the binding energy was found to be -8.63Kcal/mol. 
 
Fig 15: Snapshot of BF5 binding with 1o86 
  
 Experimental Section 
 
 
 
Department of Pharmaceutical Chemistry   85 
 
SYNTHESIS 
 
REAGENTS AND CHEMICALS USED 
2, 4-dihydroxy acetophenone, 5-nitrovanillin, p-hydroxy benzaldehyde, m-
nitro benzaldehyde, terephthaldehyde, p-chloro benzaldehyde, m-nitro benzoic 
acid, 3,4,5-trimethoxy benzoic acid, 3-methoxy benzoic acid, 2-chloro benzoic 
acid, 2,4-dichloro benzoicacid, Thionyl chloride, DMSO, Ethanol, Methanol 
dichloromethane, Dimethyl formamide, Sodium hydroxide, Potassium carbonate, 
Iodine, Hydrochloric acid, Borate buffer, Potassium chloride, Alkaline copper 
sulphate reagent, Cyanuric chloride, HEPES buffer, EDTA, Hippuryl Histidyl 
Leucine solution. 
All the reagents and chemicals were procured from Sigma Aldrich, 
Himedia and Lobachem. All the compounds procured were purified and dried, 
whenever necessary before use, following standard methods. 
 
APPARATUS USED 
Beakers, test tubes, glass rods, mechanical stirrer, reflux condenser, 
thermometer, round bottom flask, separating funnels, pipettes 
 
ANALYTICAL WORKS 
 Melting point was determined by using melting point apparatus MR-VIS, 
 visual melting range apparatus, LABINDIA and uncorrected.  
 Reactions were monitored by thin layer chromatography (TLC) on a pre- 
 coated silica gel G plated using Iodine vapor as visualizing agent.  
 UV spectra were recorded on JASCO V-530 UV-VIS spectrometer in the 
department of Pharmaceutical analysis, College of Pharmacy, SRIPMS, 
Coimbatore.  
 IR spectra were recorded on JASCO FTIR-420 series in the department of 
Pharmaceutical Analysis, College of Pharmacy, SRIPMS, Coimbatore.  
 NMR spectra were recorded on Bruker 400MHz NMR spectrometer at 
 SAIF, CUSAT, Cochin. 
 Mass spectra were recorded on Shimadzu, LC-class 2010 EV at SAIF, 
 MG University, Kottayam.  
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SCHEME 1[116-118] 
OH
OH
CH3
O +
OCH3
OH
O
NO2
OH OH
O
OCH3
OH
O2N
O
O
OH
OH
NO2
H3CO
O
O
OH
OCH3
NH2
OH
O
O
OCH3
OH
N
OH
NaOH/EtOH
I2/DMSO reflux
Fe/HCL
OHC
R
R
2,4-dihydroxy acetophenone 3-nitro-4-hydroxy-5-methoxy                  
 benzaldehyde
Schiff base of flavonoid
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COMPOUND SUBSTITUTION(R) 
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NO2
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Procedure for scheme 1 
Step 1: Synthesis of Chalcones 
A mixture of 2,4-dihydroxy acetophenone (1mmole) and 3-methoxy-4-
hydroxy-5-nitro benzaldehyde (1mmole) was stirred in ethanol and added NaOH 
(30%,10ml) drop wise to the mixture. The reaction temperature was maintained 
between 20-25 οC. After vigorous stirring for 4‐5 hours the reaction mixture was 
neutralized with 0.2N HCl. The precipitate formed was filtered and recrystallized 
from ethanol. 
 
Step 2: Synthesis of Flavonoids from Chalcones 
Iodine (0.1) was added to the solution of chalcone (1mmole) in DMSO 
(20ml) and refluxed for 1 hour. The mixture was cooled to room temperature and 
added excess of water into it. The product formed was filtered and dried. 
 
Step 3: Reduction of Nitro group: 
Flavonoids (1g) along with a pinch of zinc dust was taken in a round 
bottom flask, add conc.HCl (5ml) and ethanol (25ml) and the mixture is refluxed 
for 1 hour. After cooling to room temperature it is neutralised with 0.5molar 
Na0H.The gelatinous precipitate formed was filtered, dried and recrystallized 
with ethanol. 
 
Step4: Synthesis of Schiff bases from flavonoids- (2-(3-amino-4-hydroxy-5-      
methoxyphenyl)-7-hydroxy-4H-chromen-4-one): 
Equimolar quantities of amino flavonoid and substituted aldehyde were 
dissolved in a mixture of methanol and conc.HCl and refluxed for 2 hours. It was 
then cooled and poured into crushed ice.The product formed was obtained by 
filtration and recrystallized from chloroform. 
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SCHEME 2[79] 
OH OH
CH3
O
+
Cl
O
R
K2CO3
Dryacetone,reflux
OOH
O
O
R
R
2,4-dihydroxy acetophenone substituted benzoyl chloride substituted benzoyl flavones
  
COMPOUNDS SUBSTITUTION(R) 
BF1 
NO2 
BF2 
 
OCH3
OCH3
OCH3  
BF3 
 
Cl
 
BF4 
 
OCH3
 
BF5 
 
Cl
Cl 
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Step1: Synthesis of substituted acid chlorides 
Substituted benzoic acid (5g) was dissolved in dichloromethane. Added a 
few drops of DMF as catalyst for the reaction. Thionyl chloride (2.4g) was slowly 
added and the reaction is stirred for 2 hours. The reaction mixture was then 
evaporated; the acid chloride formed can be used without any purification.  
 
Step2: Synthesis of substituted benzoyl flavones 
To a stirred solution of 2,4-dihydroxy acetophenone (0.3mole)  in dry 
acetone added anhydrous K2CO3 and stirred at room temperature for 10 minutes. 
Added substituted benzoyl chloride (0.9moles) in small portions to the reaction 
mixture and allowed to stir for about half an hour. The reaction mixture was then 
refluxed for 24 hours. After refluxing the solvent was evaporated and the residue 
cooled to room temperature and acidified with dil.HCl. The product was dried and 
recrystallized from dichloromethane.    
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PHYSICAL CHARACTERISATION DATA 
1. Substituted Schiff bases of flavonoids 
O
O
OH
OCH3
OH
N
R  
Table 5: Physical characterisation of substituted Schiff bases of 2,4’di 
hydroxy-3’methoxy-flavonoids. 
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SB1 
OH
 
C23H17NO8 403.38 69% 107-109 0.45 
SB2 
O2N
 
C23H16N2O7 432.38 76% 117-118 0.67 
SB3 
OHC
 
C24H17NO6 415.39 73% 126-127 0.78 
SB4 
Cl
 
C23H19NO7 421.82 65% 180-182 0.59 
SB5 
OH
H3CO
 
C24H19NO7 433.41 72% 135-136 0.47 
 
Recrystallization : Chloroform 
Solvent system : Chloroform: water (7:3) 
Visualizing agent : Iodine vapour 
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2. Physical characterisation of Substituted 3-benzoyl flavones 
OOH
O
O
R
R
 
Table 6: Physical characterisation of 3-substituted Benzoyl flavones 
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BF1 
NO2 
C22H12N2O8 432.33 81% 108-109 0.57 
BF2 
OCH3
OCH3
OCH3  
C28H26O10 522.50 79% 222-223 0.56 
BF3 
Cl
 
C22H12Cl2O4 411.23 74% 110-111 0.78 
BF4 
OCH3
 
C24H18O4 402.39 77% 135-136 0.39 
BF5 
Cl
Cl 
C22H10Cl4O4 480.12 84% 128-129 0.42 
    
Recrystallization  :  Dichloromethane 
Solvent system :  Chloroform: Water (4:5) 
Visualizing agent  :  Iodine vapour 
 Experimental Section 
 
 
 
Department of Pharmaceutical Chemistry   93 
 
SPECTRAL ANALYSIS OF COMPOUNDS 
The structures of synthesized compounds during the present investigation 
were established on the basis of chemical data IR, UV, NMR, and MASS spectral 
data. The purity of the compounds was established by single spot on TLC plates. 
 
COMPOUND CODE: SB1 
OOH
O
O
OH
N
CH3
OH  
Chemical name 
7-hydroxy-2-{4-hydroxy-3-[(Z)-(4-
hydroxybenzylidene)amino]-5-methoxyphenyl}-
4H-chromen-4-one 
UV Spectrum 
Solvent used  : methanol 
λ max          : 284nm 
IR (KBR, Vmax in cm-1) 
 
3201.26(aromatic OH), 1217.83(cyclic ester-C-O-
C), 1669.09 (C=N), 1779.01(C=O), 1602.56 
(C=C), 2878.24 (C-H) 
1HNMR spectral data 
 
2.732 (s, 3H, Ar-OCH3) , 6.245-6.388 (s, 3H, Ar-
OH) , 7.736-8.612 (m, 9H). 
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Mass Spectral Data 
Sl 
No: 
Fragments m/z value 
 
 
 
1 
OOH
O
O
OH
N
CH3
OH
+
 
 
 
 
403 
 
 
2 
O
O
OH
+
 
 
 
162 
 
 
3 
NH
OH
+
 
 
 
121 
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UV SPECTRUM 
Fig:16 UV Spectrum of compound SB1 
IR SPECTRUM
 Fig:17 IR Spectrum  of  Compound SB1 
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 1H NMR SPECRUM 
fig 18: 1HNMR Spectrum of compound SB1 
 
MASS SPECTRUM 
 
Fig 19: Mass spectrum of compound SB1 
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COMPOUND CODE:  BF1 
OOH
O
O
N
+
O
-
O
N
+ O
-
O
 
 
Chemical name 
7-hydroxy-3-(3-nitrobenzoyl)-2-(3-
nitrophenyl)-4H-chromen-4-one 
UV Spectrum 
Solvent : dichloromethane 
λmax     : 270nm 
IR (KBR, Vmax in cm-1) 
3404.81(aromatic OH), 1840.72 
(aromatic C=O), 1591.95(NO2) , 
1618.95 (C=C) , 1706.69 (aliphatic 
C=O) ,3087.48 (C-H) 
1HNMR Spectral data 
6.792 (s, 1H, Ar-OH) 
6.928-8.350  (m, 11 H, Ar-H & CH=C) 
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Mass Spectral Data 
Sl No: Fragments m/z value 
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UV SPECTRUM 
 
Fig 20: UV spectrum of compound BF1 
IR SPECTRUM 
Fig 21: IR spectrum of compound BF1 
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1HNMR SPECTRA 
 
Fig 22: 1HNMR spectrum of compound BF1 
MASS SPECTRA 
 
Fig 23: Mass spectrum of compound BF1 
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Extraction of angiotensin converting enzyme from sheep lung extract[119,120] 
Sheep lungs was collected from slaughterhouse and one gram of sheep 
lung tissue was diced and homogenised in 10 ml of the ice cold 100 mM borate 
buffer (pH-8.3) containing 50 mM KCl using a homogenizer at 4°C. The 
homogenate was centrifuged at 8000g at 4°C for half an hour, and the supernatant 
was collected. Remove any molecular impurities if present and stored at 4oC. This 
supernatant was used as the source of ACE. 
Estimation of protein content by Lowry method [121] 
Different dilutions of Bovine serum albumin (0.2-1μg/ml) were prepared 
from stock BSA solution (1mg/ml) in a test tube. The final volume in each test 
tube was adjusted to 5ml with distilled water. From these dilutions, pipette out 
0.2ml protein solution to different test tubes and add 2ml of alkaline copper 
sulphate reagent (analytical reagent) and mix well. The solution was incubated for  
10 minutes at room temperature. Then add 0.2 ml of Folin Ciocalteau solution to 
each test tube and incubated for 30 minutes. The colorimeter was set to zero with 
blank and the optical density was measured at 450 nm. Plot the absorbance 
against protein concentration to get a standard calibration curve. Check the 
concentration of unknown samples and determine the concentration of unknown 
from the standard curve.  
Estimation of ACE from sheep lung extract [119] 
ACE inhibitory activity was measured by using Hippuryl-L-histidyl-L-
leucine (HHL) as substrate. This reaction mixture contained 0.2ml of 5mM HHL 
prepared in 200mM borate buffer (pH 8.3) with 1000 mM KCl. The reaction was 
initiated by the addition of different concentration of lung extract and then 
incubated at 37οC foe 30 minutes. The reaction was stopped by addition of 2ml of 
HEPES buffer and 1ml of 136 mM cyanuric chloride in 1,4-dioxan and yellow 
colour developed was measured at 405nm.Various concentration of hippuric acid 
(which is formed by the reaction of ACE on HHL) were used for the preparation 
of standard graph. 
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In vitro angiotensin converting enzyme inhibitory activity [119] 
Colorimetric Method 
The reaction mixture contained 5mM HHL prepared in 200mM Borate 
buffer (pH8.3), containing 1000mM KCl 10μl of different concentration of 
unknown drug sample (50-800μg), lung extract (50μl)and distilled water in a 
volume of 1ml. The reaction mixtures were incubated at 37οC for 30 minutes. The 
reaction was stopped by adding 2ml of HEPES buffer (pH 9), which contain 
2.5mM EDTA. Finally add 1ml of 136mM cyanuric chloride in 1,4- dioxan was 
added to the reaction mixture and shake vigorously for 15 seconds. The 
absorbance of yellow colour developed was measured at 405nm. Lisinopril was 
used as the standard drug for comparison with the assay system.  
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RESULTS 
Estimation of sheep lungs extract (ACE) 
Estimation of sheep lung extract was used to estimate the protein and 
plotting the calibration curve of ACE. 
Estimation of protein in lung extract (ACE) 
Table 7: Absorbance of Bovine serum albumin (BSA) 
Concentration 
(μg/ml) 
Absorbance at 450nm Average 
absorbance 
Abs1 Abs2 Abs3 
0.2 0.1256 0.1430 0.1524 0.1403 
0.4 0.2132 0.2038 0.1987 0.2052 
0.6 0.2432 0.2469 0.2571 0.2499 
0.8 0.3178 0.3253 0.3215 0.3213 
1 0.3855 0.3253 0.3802 0.3810 
 
Table 8: Absorbance of lungs extracts (ACE) 
Volume of lung extract 
(μl) 
Absorbance at 450nm 
Average 
Abs1 Abs2 Abs3 
10 0.1721 0.1734 0.1854 0.1779 
20 0.2956 0.3158 0.2478 0.2816 
 
 Experimental Section 
 
 
 
Department of Pharmaceutical Chemistry   104 
 
 
Fig 24: Standard curve for protein estimation 
Table 9: Interpolation of lungs extract 
Volume of lung 
extract (μl) 
Interpolating 
value 
In 100 
μl 
In 1 
ml 
Average 
10 0.2987 2.987 29.87 49.99 
μg/ml 20 0.7011 7.011 70.11 
                      =49.99 x10=499.90μg/ml 
Protein content of lung extract (ACE) is 499.90μg/ml 
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Estimation of ACE from sheep lung extract 
Table 10: Absorbance of Hippuric Acid 
Concentration of 
hippuric acid 
(μM) 
Absorbance at 405nm 
Average  
absorbance Abs1 Abs2 Abs3 
0.2 0.4239 0.4250 0.4147 0.4212 
0.4 0.4771 0.4640 0.4846 0.4752 
0.6 0.5324 0.5275 0.5441 0.5346 
0.8 0.5897 0.5979 0.5820 0.5898 
1 0.6496 0.6509 0.6494 0.6880 
1.2 0.7094 0.7126 0.7081 0.7100 
1.4 0.7881 0.7763 0.7659 0.7767 
 
Table 11: Absorbance of sheep lungs extract (ACE) 
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100 0.2760 0.2850 0.2842 0.2817 - - 
 
405.323 
200 0.3921 0.3946 0.3897 0.3921 - - 
300 0.5182 0.5298 0.5104 0.5614 0.6945 431.965 
400 0.6413 0.6459 0.6471 0.6447 0.9671 413.607 
500 0.7612 0.7624 0.7598 0.7611 1.3499 370.397 
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Fig 25:Calibration curve of Hippuric Acid 
                                1Unit of ACE =405.323μl of Sheep lung Extract  
In vitro Angiotensin Converting Enzyme Inhibitory Activity  
Table 12:  In vitro ACE inhibitory activity of standard drug (Lisinopril) 
Concentration of Lisisnopril  (μg/ml) Percentage inhibition 
10 31.13±28 
20 50.48±25 
40 65.12±04 
80  80.08±36 
160 90.95±28 
IC 50 19.85±24 
concentration
ab
so
rb
an
ce
Calibration curve oof Hippuric acid
DPlot
Trial
Version
http://www.dplot.com
0.15 0.3 0.45 0.6 0.75 0.9 1.05 1.2 1.35
0.4
0.45
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.6945 
0.9671 
1.3499 
 Experimental Section 
 
 
 
Department of Pharmaceutical Chemistry   107 
 
ACE inhibitory activity of synthetic compounds 
Table 13: In Vitro ACE inhibitory activity of synthetic compounds SB 1-5 
Concentration 
(μg/ml) 
Percentage inhibition(%) of ACE 
SB1 SB2 SB3 SB4 SB5 
50 32.90±24 37.22±34 27.39±29 31.71±17 23.41±39 
100 48.88±14 60.17±39 40.78±20 53.10±45 44.01±31 
200 63.97±52 71.86±17 58.87±30 61.83±46 57.92±25 
400 79.86±15 84.06±18 76.87±37 78.33±17 71.94±11 
800 89.28±17 91.38±34 93.92±24 86.26±67 84.81±09 
IC 50 110.12±54 81.54±26 162.32±33 95.64±09 149.97±18 
All the determinations were carried out in triplicate and the values are expressed as a mean ± SEM  
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Table 14: In Vitro ACE inhibitory activity of synthetic compounds BF 1-5 
Concentration 
(μg/ml) 
Percentage inhibition (%) of ACE 
BF1 BF2 BF3 BF4 BF5 
50 24.94±19 17.19±23 46.58±35 22.38±22 46.52±37 
100 30.07±31 30.16±37 57.41±47 37.81±11 59.34±37 
200 45.15±65 43.13±35 76.03±09 57.13±36 73.61±29 
400 64.59±52 54.76±09 82.60±57 66.49±21 80.08±36 
800 73.89±24 65.99±57 88.05±05 78.85±18 90.58±28 
IC50 259.65±42 325.36±17 70.21±35 165.52±22 73.89±24 
All the determinations were carried out in triplicate and the values are expressed as a mean ± SEM. 
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Fig 26:ACE  Inhibitory Activity of Lisinopril 
 
Fig 27: ACE Inhibitory Activity of Synthetic compounds SB1-SB5 
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Fig 28: ACE Inhibitory Activity of Synthetic compounds BF1-BF5 
ACE inhibitory activity of synthetic flavonoids. 
Hypertension is one of the major chronic diseases. Angiotensin converting 
enzyme (ACE) is one of the major regulators of blood pressure and inhibition of 
this enzyme will leads to lowering of blood pressure. ACE is a membrane bound 
enzyme present on the luminal surface of vascular endothelium and therefore 
remains in close contact with -circulation. It is particularly abundant in lung which 
has a vast surface area of vascular endothelium. Therefore the lung serves as 
major organ for the production of circulating angiotensin II. In this study the ACE 
enzyme was extracted from sheep lungs and used for in vitro study. There are 
different in vitro methods for the determination of ACE inhibitory activity. The 
assay is based on the hydrolysis of hippuryl-L-histidyl-leucine (HHL) by ACE. 
The amount of hippuric acid formed in reaction is determined by measuring the 
absorbance at 405 nm. The difference of absorbance in the absence and presence 
of inhibitor is proportional to the inhibitory activity of tested sample.  
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In this assay, estimation of protein content and estimation of ACE in the 
lung extract was done. Protein estimation was done by using Lowry method. 
Different concentrations of (BSA) bovine serum albumin (0.2 to 1 μg/ml) were 
used for the preparation of the standard graph and the estimation of protein in 
different volumes of lung extract was obtained by interpolating the average 
absorbance in the calibration curve of BSA. About 10 ml of the lung extract 
contains 499.90 μg/ml of protein (Table no.9) 
Estimation of ACE in the sheep lung extract was done by using HHL as 
substrate. The standard curve was plotted by taking concentration of hippuric acid 
in X-axis and absorbance on Y-axis. The   amount of ACE was estimated by 
interpolating the average absorbance value of different volumes of sheep lung 
extract in the standard curve. From the table it was found that 1 unit of ACE is 
contained in 405.323 μl of sheep lung extract. 
The Schiff bases of flavonoids (SB1-5) and 3-subtituted benzoyl flavones 
(BF1-5) were tested for their in vitro angiotensin converting enzyme activity at 
various concentrations ranging from 50μg/ml to 800μg/ml. A dose dependent 
increase in percentage inhibition was noticed for all the compounds. The IC50 
values were obtained by plotting a standard graph with percentage inhibition 
versus concentration in μg/ml. The values obtained were compared with that of 
standard drug lisinopril.  
The standard drug lisinopril exhibited 31.13% inhibition of ACE at a 
concentration of 10 μg/ml. An increase in inhibition to 90.95% was observed at 
160μg/ml and the IC50 value was found to be 19.85μg/ml. A dose dependent 
increase in percentage inhibition was observed for all tested concentration. 
 The Schiff bases of flavonoids (SB1-5) were found to inhibit ACE and 
produced 32.90%, 37.22%, 27.39%, 31.71%, 23.41% inhibition respectively at a 
concentration of 50μg/ml and the percentage inhibition was increased with an 
increase in concentration and reached to 89.28%, 91.38%, 93.92%, 86.26% and 
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84.81% respectively at 800μg/ml. The IC50 values of the synthesized compounds 
were found to be 110.12 μg/ml, 81.54 μg/ml, 112.32 μg/ml, 95.64 μg/ml and 
149.97 μg/ml. The order of potency of the compounds were found to be 
SB2>SB4>SB1>SB5>SB3. From the results obtained with Schiff bases of 
flavonoids it can be confirmed that SB2 and SB4 produced excellent ACE activity 
since these two compounds could inhibit the ACE enzyme at lower concentration 
compared to other compounds used in the study.  
 The results of 3-subtituted derivatives of benzoyl flavones (BF1 to BF5) 
similarly exhibited ACE inhibition of 24.94%, 17.19%, 46.58%, 22.35%, and 
46.52% respectively at 50 μg/ml and at 800 μg/ml the percentage inhibition 
increased to 73.89%, 65.99%, 88.05%, 78.85%, 90.58% respectively. IC50 values 
obtained for these compounds were found to be 259.65 μg/ml, 325.36 μg/ml, 
70.21 μg/ml, 165.52 μg/ml and 73.89 μg/ml. The order of potency of benzoyl 
flavone derivatives was found to be BF3> BF5> BF4> BF1>BF2. Among the five 
compounds synthesized in 3-subtituted benzoyl flavones derivatives BF3 and BF5 
exhibited better ACE inhibition. The obtained results when compared with 
standard lisinopril are much lesser in terms of percentage inhibition and this can 
be overcome if the compounds purity is enhanced.  
 All the synthesized derivatives exhibited moderate potency to inhibit ACE. 
The compounds BF3, BF5 and SB2 and SB4 offered comparatively highest 
inhibitory activity. Compound BF2 showed the lowest potency with an IC50 value 
325.36 μg/ml. 
 ACE inhibitory ability of all the synthesized compounds was found to be 
less than that of the standard drug. Activity of compounds largely depends on the 
substitutions on the nucleus. Introduction of an electron withdrawing group results 
in increased activity. Electron donating substituents resulted in decreased activity. 
Substitution on meta position of aromatic ring resulted in decreased activity, while 
substitution on ortho and para positions resulted in an increased of ACE inhibitory 
activity.  
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SUMMARY AND CONCLUSION 
SUMMARY 
The present study is focussed on the designing and synthesis of some 
novel flavonoid derivatives and evaluation of their possible Angiotensin 
converting enzyme inhibitory activity. For this the following approaches has been 
adopted. 
Phase 1: Literature review 
Literature review provides a solid background to the back one’s 
investigation. It plays a critical role in analysing the existing literature. Literatures 
reported flavonoids as a good lead for ACE inhibition. 
Phase 2: Drug design approach 
It involves the following steps 
1) Identification of drug target 
ACE was selected as the target enzyme for the antihypertensive activity. 
2) Lead identification 
The lead molecule flavonoid was selected based on literature reviews. 
Various naturally occurring flavonoids were reported to have Angiotensin 
converting enzyme inhibiting activity. 
3) Lead optimization 
Lead optimization is an operationally diverse stage in which the chemical 
structure of compounds is modified to improve the specificity and selectivity. 
Lead optimization was done by observing the computational drug likeness 
properties. All the 10 compounds possessed good drug likeness score and good 
oral bioavailability. Hence were eligible for further study. 
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4) Molecular docking studies 
Molecular docking study was done by using Autodock4.2. The target 
enzyme ACE was downloaded from RCSB protein data bank (pdb ID: 1o86). The 
ligands were subjected to docking and most of the compounds showed binding 
energy to the enzyme higher than that of standard drug (Lisinopril) used. The 
ligands SB2, SB4, SB3, SB1, BF5, BF3 were showing best docked to1o86. 
 
Phase 3: Synthesis 
In this work, 10 new compounds were synthesized. Two schemes were 
developed for the synthesis of compounds. Resacetophenone was used as the 
starting material for both schemes. 
In the first scheme resacetophenone reacted with nitro substituted vanillin 
to form chalcone in presence of ethanol and sodium hydroxide. This formed 
chalcone was subjected to cyclisation in presence of iodine and DMSO. The 
product formed was nitro substituted flavonoid and was further reduced to convert 
the nitro group into amino group. Finally Schiff bases were prepared from this 
amino flavonoid by reaction with various substituted benzaldehydes. 
In the second scheme various substituted benzoyl chlorides were prepared 
from corresponding benzoic acids and treated with resacetophenone which was 
refluxed for 24 hours to obtain desired products (substituted benzoyl flavones). 
 
Phase 4: Physical characterisation 
Melting points and Rf value of all the compounds are found out. 
 
Phase 5: Spectral characterisation 
The structures of the synthesized compounds are established based on the 
UV, IR, 1HNMR and Mass spectral data. 
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Phase 6: Evaluation of in vitro Angiotensin converting enzyme inhibitory 
activity. 
 
All the newly synthesized ligands were screened for their angiotensin 
converting enzyme inhibitory activity by using modified Cushman and cheung 
method. All compounds showed ACE inhibitory activity. The order of potency of 
synthesized compounds against ACE were 
Scheme 1: SB2> SB4> SB1> SB5> SB3 
Scheme 2: BF3> BF5> BF4> BF1> BF2 
 
The synthesized compounds exhibited moderate ACE inhibitory activity. 
It was observed that nature, position and size of the substituent plays a crucial role 
in the determination of inhibitory activity of the compound. The compounds BF3, 
BF5, SB2 and SB4 were found to be more potent in inhibiting the ACE. BF3 was 
found to be more potent with an IC50 value of 71.25μg/ml. This class of drug 
prevents the formation of Angiotensin I to Angiotensin II by inhibiting ACE, 
which will results in the lowering of blood pressure and can be used in the 
treatment of hypertension. 
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CONCLUSION 
 The basic aim of the present work is to identify the correct conformation 
of ligands in the active site of enzyme and also to predict their affinity 
towards the enzyme. 
 Computational drug designing approach helps in minimizing the 
wearisome process of drug discovery and delivers a new drug candidate 
more rapidly. 
 The drug likeness proved the compounds to be orally bioactive 
 Docking results established the possibility of flavonoid moiety to possess 
Angiotensin converting enzyme inhibitory activity. 
 The 10 derivatives were synthesized based on the schemes which are 
previously fixed and it led to good yields. 
 Physical characteristics of the compounds were confirmed by melting 
 point  and Rf value. 
 Structure of the compounds were finally confirmed by UV, IR 1HNMR 
 and  Mass spectral studies. 
 The synthesized compounds were subjected to the in vitro ACE inhibitory 
 activity. 
 Derivatives of the flavonoids exhibited moderate activity against ACE. 
These leads to the inference that all the 10 newly synthesized compounds 
possess angiotensin converting enzyme inhibitory activity. Novel structure 
based drug designing methods helped to screen various compounds for a 
specific activity within a short period of time. 
         Further in vivo studies with these tested synthetic flavonoids have to be 
carried out to corroborate the result of in vitro activity.  The present work could 
be considered as a propitious step for finding the prominence of flavonoid moiety 
in the treatment of hypertension by inhibiting the key enzyme ACE. 
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LIST OF NEWLY SYNTHESIZED COMPOUNDS 
Scheme 1 
O
O
OH
OCH3
OH
N
R  
Sl 
No. 
Compound 
code 
Chemical name Structure 
1 SB1 
7-hydroxy-2-{4-
hydroxy-3-[(Z)-(4-
hydroxybenzyliden
e)amino]-5-
methoxyphenyl}-
4H-chromen-4-one 
 
OOH
O
O
OH
N
CH3
OH  
2 SB2 
7-hydroxy-2-{4-
hydroxy-3-
methoxy-5-[(E)-
(3-
nitrobenzylidene)a
mino]phenyl}-4H-
chromen-4-one 
 
O
O
OH
OH
O
N
CH3
N
+
O
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3 SB3 
4-[(Z)-{[2-
hydroxy-5-(7-
hydroxy-4-oxo-
4H-chromen-2-yl)-
3-
methoxyphenyl]im
ino}methyl]benzal
dehyde 
 
O
O
OH
O
OH
N
CH3
O  
4 SB4 
2-{3-[(Z)-(4-
chlorobenzylidene)
amino]-4-hydroxy-
5-
methoxyphenyl}-
7-hydroxy-4H-
chromen-4-one 
 
OOH
O
O
OH
N
CH3
Cl
 
5 SB5 
7-hydroxy-2-{4-
hydroxy-3-[(Z)-(4-
hydroxy-3-
methoxybenzylide
ne)amino]-5-
methoxyphenyl}-
4H-chromen-4-one 
 
O
O
OH
O
OH
N
CH3
O
OH
CH3
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                                                Scheme 2 
OOH
O
O
R
R
 
Sl 
no: 
Compound 
code 
Chemical name Structure 
1 BF1 
7-hydroxy-3-(3-
nitrobenzoyl)-2-(3-
nitrophenyl)-4H-
chromen-4-one 
 
OOH
O
O
N
+
O
-
O
N
+ O
-
O
 
2 BF2 
7-hydroxy-3-(3,4,5-
trimethoxy benzoyl)-
2-(3,4,5-
trimethoxyphenyl)-
4-H-chromen-4-one 
OOH
O
O
O
O
O
O
O
O
CH3
CH3
CH3
CH3
CH3
CH3
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3 BF3 
3-(2-chlorobenzoyl)-
2-(2-chlorophenyl)-
7-hydroxy-4H-
chromen-4-one 
OOH
O
O
Cl
Cl
 
4 BF4 
7-hydroxy-3-(3-
methoxybenzoyl)-2-
(3-methoxyphenyl)-
4H-chromen-4-one 
 OOH
O
O
O
CH3
O
CH3
 
5 BF5 
3-(2,4-
dichlorobenzoyl)-2-
(2,4-
dichlorophenyl)-7-
hydroxy-4H-
chromen-4-one 
 
O
O
OH
Cl Cl
O
Cl
Cl  
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